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SUMMARY
With the greater availabilty and success of dialysis and renal 
transplantation programmes, cardiovascular disease has emerged as the 
dominant threat to survival of patients with end-stage renal failure. The 
identification of left ventricular hypertrophy as an independent 
determinant of outcome in such patients prompted this investigation into 
factors which might influence left ventricular mass. Reports of regresson 
of ventricular hypertrophy after renal transplantation suggested correction 
of uraemia, anaemia or hyperparathyroidism, either alone or in 
combination might be important.
The aim of this thesis therefore was to examine the left ventricle by 
means of established echocardiographic techniques in dialysis patients in 
relation to different therapeutic interventions. Patients were studied 
before and after renal transplantation, treatment with recombinant human 
erythropoietin for anaemia, and surgical parathyroidectomy for 
hyperparathyroidism. Stable dialysis patients were also studied at 
intervals.
Three hundred and seventy eight echocardiograms in 223 patients 
were performed and analysed by the author. A cross-sectional study of 
echocardiograms from dialysis patients revealed that men had greater left 
ventricular mass indices (LVMI) than women, after adjusting for body 
surface area. LVMI tended to increase with age, and was greatest in 
diseases associated with severe hypertension. Serial changes in LVMI 
followed no predictable pattern but correlated with changes in systolic 
blood pressure and haemoglobin. There were no differences between 
CAPD and haemodialysis subjects.
Following renal transplantation, the expected decrease in LVMI 
was not observed. However LV dimensions did change in most patients.
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A search for factors which might be associated with these changes 
revealed that the most anaemic patients at the time of surgery had a 
greater reduction in end-diastolic dimension (EDO), while those with 
functioning arteriovenous fistulae had persisting elevation of EDO. Using 
multiple logistic regression analysis, systolic blood pressure and male 
sex were related to the pre-operative LVMI. Age at the start of dialysis 
treatment was the only covariate to be associated with outcome.
Successful treatment of renal anaemia with erythropoietin was 
associated with a small reduction in LVMI and LV wall thickness. 
Parathyroidectomy in dialysis patients resulted in similar changes.
Variability in response was a consistent feature in all of the study 
groups and led to further investigation of the influence of volume overload 
by assessing ventricular changes as a result of dialysis with fluid removal. 
Highly significant changes in all left ventricular diastolic dimensions were 
observed, indicating that the widely used method of determining LV mass 
is not suitable for serial assessment of dialysis patients who are subject 
to changes in fluid balance.
12
Chapter 1
CARDIOVASCULAR MORTALITY IN CHRONIC RENAL DISEASE
"The enlarged state of the heart would seem to bespeak some 
cause of obstruction to the circulation through the system beyond what 
we discovered". [Richard Bright, 1827 (1)].
An association between renal impairment and cardiac disease has 
been recognised since Bright described the post-mortem findings in 
twenty-five patients dying with nephrotic syndrome, seven of whom had 
enlargement of the heart. However, only with the introduction of effective 
renal replacement therapy (RRT), has cardiovascular disease emerged 
as the dominant threat to survival in end-stage renal failure (ESRF).
Section 1
Cardiovascular mortality and chronic renal disease - population data
A decline in the number of deaths from renal disease has been 
accompanied by an increase in deaths from cardiac disease in the 
general population over the past eight decades (2). This in part might be 
explained by the development, greater availability and success of 
techniques of dialysis and renal transplantation, without which people 
with ESRF could not survive. Nevertheless premature death among 
patients receiving RRT is unexpectedly common and data from the 
Registry of the European Dialysis and Transplant Association (EDTA), 
confirm that cardiovascular disease accounts for over half of these deaths 
(3).
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The principal "cardiovascular" causes of death described by the 
EDTA during the last two decades are myocardial infarction, cardiac 
failure, cardiac arrest and cerebrovascular accident (Figure 1). As in the 
general population, coronary heart disease is reported more frequently in 
males, and in northern European countries (4,5) (Figure 2), although the 
relative risk of death from myocardial infarction (Ml) in dialysis and 
transplant patients is far greater. In the United Kingdom, this relative risk 
in patients receiving renal replacement has been estimated to be at least 
five times higher than in age and sex matched subjects from the general 
population and in younger patients with end-stage renal disease (ESRD) 
the risk is almost ninety-fold. Overall the death rate in ESRF is equivalent 
to rates observed in patients with a history of a previous Ml (5).
The underlying cause of renal failure also determines susceptibility 
to a cardiovascular event: with diabetes and renovascular hypertension 
the risk of Ml and cerebrovascular accident is greater, than if 
glomerulonephritis is the primary renal disease (3). Furthermore the 
distribution of cardiovascular causes of death differs according to the type 
of renal replacement therapy (figure 3): following renal transplantation 
cardiac failure and cerebrovascular accidents are less frequently 
reported, while Ml is observed as often in spite of transplanted patients 
tending to be fitter before acceptance for such surgery (6). Cardiovascular 
mortality is highest in the first year of treatment, be it transplantation or 
dialysis (7,8). In dialysis patients, the proportions of deaths from specific 
cardiovascular causes do not vary significantly with the method of dialysis 
employed (figure 3).
Although these data are incomplete (in 1989, 79% of centres in 
Europe submitted figures to EDTA) and the accuracy of diagnoses and 
death certification might be questioned, cardiovascular disease in 
patients with renal failure is a major problem in all countries offering renal
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support (9) and shows no sign of abating (10). The reasons the loss from 
cardiovascular disease is so great are still disputed. Some authors claim 
that atherosclerosis is accelerated by prolonged haemodialysis treatment 
(11), while others explain the high mortality by an observed excess of the 
accepted cardiovascular risk factors (12,13,14).
Section 2
Cardiovascular risk factors and renal disease
Advanced renal impairment is invariably complicated by 
disturbances of electrolyte, fluid, endocrine and metabolic balance which 
lead in turn to volume overload, hypertension, anaemia, and 
hyperlipidaemia. Moreover, the primary renal disease, dietary and drug 
therapy, the method of renal replacement and altered lifestyle may further 
disrupt normal homeostasis. As a result, risk factors known to predispose 
to cardiac mortality, are frequently present in patients with ESRF, and 
additional risks conferred by uraemia or its treatment have been 
proposed (Table 1).
CARDIOVASCULAR RISK FACTORS
Accepted Proposed
age sex hypertension hyperlipidaemia cigarette smoking glucose intolerance ventricular hypertrophy
anaemia arteriovenous fistula hyperparathyroidism nicotine retention acetate dialysis transplant rejection malnutrition
Table 1 Cardiovascular risk factors in ESRD
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The cardiovascular risk factors listed can be described as 
"vascular" - those which promote atherogenesis, or "ventricular" - factors 
affecting ventricular size or function. Some, are associated with both 
vascular and ventricular disease. The vascular risks in ESRD will be 
described briefly (sections 1.3-1.6) and left ventricular influences 
discussed in greater detail in Chapters 2, 3 and 4.
Section 3
Cigarette smoking and vascular disease in ESRF
Habitual tobacco consumption is common among patients with 
chronic illness (15), and in men receiving haemodialysis has been 
associated with an increased incidence of fatal Ml and stroke (16). 
Hypertensive smokers on haemodialysis have a particularly poor 
prognosis and it has been suggested that exaggerated nicotine retention 
may predispose to cardiovascular disease (17). Smoking is also 
independently correlated with the development of cardiovascular 
complications after renal transplantation, although one group suggests 
the risk attributable to cigarettes is small (18).
Section 4
Hyperlipidaemia and vascular disease in ESRF
Another factor contributing to premature cardiovascular mortality is 
hyperlipidaemia, prevalent in both chronic and end-stage renal failure. It 
has long been considered part of the nephrotic syndrome, though the 
pathophysiology is still incompletely understood (19). Elevated 
cholesterol, low-density lipoprotein (LDL) and apoprotein B
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concentrations, together with reduced levels of protective high-density 
lipoprotein (HDL) might suggest increased cardiovascular risk, but 
evidence for this is contradictory (20,21); heavy proteinuria however 
would seem to be associated with a higher than expected incidence of 
coronary heart disease (22).
Abnormal lipid metabolism has also been found in non-nephrotic 
renal disorders. As renal function deteriorates various lipase activities 
become impaired, resulting in defective triglyceride clearance and further 
exacerbated by a degree of insulin resistance (23,24). In addition HDL 
levels tend to fall while reduced receptor affinity for uraemic LDL results 
in higher circulating concentrations (25). In spite of these changes total 
cholesterol levels are often normal but lipoprotein composition altered, in 
such a way that catabolism yields atherogenic remnants (26).
A similar pattern of hypertriglyceridaemia with normal or low 
cholesterol has been described in patients treated by maintenance 
haemodialysis or CAPD (27). After dialysis patients undergo renal 
transplantation, their lipid profiles change, but usually remain abnormal: 
hypertriglyceridaemia improves though persists in twenty percent, while 
cholesterol fractions rise (28). In contrast to experience in large 
hyperlipidaemic populations (29,30), there is no evidence that use of 
lipid-lowering drugs in renal patients will reduce the incidence of Ml.
Section 5
Glucose intolerance and vascular disease In ESRF
Over 10% of new patients now accepted for "long term" renal 
replacement therapy (RRT) in Europe are diabetic, and therefore at 
increased risk of developing cardiovascular disease (31). The three year 
survival of 25 to 35 year olds with diabetic nephropathy starting dialysis
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but not transplanted is only 60%, compared to 85% In all similarly aged 
RRT patients (4). Although the mortality from Ml is greater in diabetic 
patients (5), the majority of deaths are sudden, of unknown cause, and 
notably often associated with cardiomegaly (32).
Transplanted diabetic patients also have a poor prognosis: in a 
study of 100 insulin dependent diabetics with ESRF undergoing pre­
transplant assessment, 37 had significant cardiac disease (advanced 
coronary occlusive disease and/or significant left ventricular dysfunction) 
(33). Fifty-eight were later transplanted and among those with pre­
existing double or triple coronary vessel disease, mortality was high. Less 
severe coronary artery narrowing was also shown to progress after renal 
transplantation. The importance of pre-operative vascular disease in 
relation to prognosis after renal transplantation has been substantiated 
(34,35) and now full pre-operative cardiac investigation is advocated. The 
death rate from myocardial infarction and ischaemia in transplanted 
diabetic patients consistently exceeds the rate in non-diabetic transplant 
recipients (5), but is disproportionately high in the first week (31).
Flow might "at risk" diabetic patients be identified? The duration of 
diabetes before ESRF is inversely correlated to survival thereafter (36), 
but there are few pointers. The absence of coronary artery narrowing on 
coronary arteriography is not necessarily reassuring as disease of small 
vessels may lead to the development of a "diabetic cardiomyopathy" and 
premature death (37,38). Fiowever among dialysis patients, there is no 
evidence that diabetics have an excessive degree of systolic myocardial 
dysfunction, compared with non-diabetics (39). On the other hand, 
diastolic ventricular compliance may be impaired in diabetics with 
proteinuria, perhaps reflecting early hypertensive heart disease (40).
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Section 6
Hypertension and vascular disease in ESRF
As the glomerular filtration rate falls, the prevalence of 
hypertension increases and reaches eighty percent in patients with ESRD 
(41,42). Patients with hypertension secondary to renal parenchymal 
disease have a significantly higher cardiovascular mortality even before 
they reach end-stage renal failure, than men and women with 
hypertension resulting from other causes (43). Those with renovascular 
disease are also recognised to be at increased risk (3). Ischaemic heart 
disease is the leading cause of death to account for this high age- 
adjusted mortality in hypertensive patients with underlying renal disease, 
many of whom have high blood pressures despite treatment, and 
electrocardiographic (EGG) abnormalities. In a study which examined the 
degree of atherosclerosis in the iliac vessels of fifty haemodialysis 
patients about to undergo renal transplantation, age and hypertension 
were related to moderate and severe vascular disease, and without 
exception, all young patients with diseased vessels had been 
hypertensive (44).
Mortality is especially high in hypertensive patients with EGG 
evidence of left ventricular hypertrophy or previous Ml (45). Moreover 
data from the Framingham study suggest that the risk associated with 
electrocardiographic left ventricular hypertrophy is greater than the risk 
attributable to hypertension alone (46). Thus, it is now clear that the high 
death rate among hypertensive patients cannot be explained solely by 
vascular disease. Left ventricular hypertrophy is an additional risk factor 
for cardiac mortality in hypertension, and indeed is a stronger predictor of 
hypertensive complications than blood presure itself (47).
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Cardiac hypertrophy was not perceived as posing special risk to 
patients already suffering the multiple problems of chronic renal failure, 
until Silberberg published his important study showing left ventricular 
hypertrophy to be an independent determinant of survival in patients with 
end-stage renal disease (48).
20
Chapter 2
RISKS ASSOCIATED WITH LEFT VENTRICULAR HYPERTROPHY
Before considering the heart in chronic renal disease, the 
prevalence, pathogenesis and prognosis of left ventricular hypertrophy in 
general will be reviewed.
Section 1
Left ventricular hypertrophy in the general population
Reports from the Framingham Study first indicated that 
abnormalities of the electrocardiogram suggestive of left ventricular 
hypertrophy are associated with an increased risk of fatal coronary heart 
disease (49) and sudden death (50) in the general population. However, 
electrocardiographic changes may be absent in genuine cases of cardiac 
hypertrophy, irrespective of the criteria employed, and echocardiography 
is undoubtedly a more sensitive method for detecting increased left 
ventricular mass (51,52).
Subsequent echocardiographic studies from Framingham have 
pointed to a prevalence of left ventricular hypertrophy of 16% in men and 
19% in women (53), in contrast to previous electrocardiographic 
estimates of 3.2% (46).
The earlier observations linking left ventricular hypertrophy to an 
increased incidence of cardiovascular events have not only been 
confirmed, but elaborated: in middle-aged and elderly men and women 
left ventricular hypertrophy is associated with cardiovascular disease, 
death from cardiovascular disease and death from all causes (54). The 
greater the left ventricular mass, the greater is the risk of non-fatal and
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fatal cardiac events, and the relationship persists after adjusting for age, 
diastolic blood pressure, smoking, obesity, diabetes and other variables. 
Left ventricular hypertrophy has therefore become established as an 
independent cardiovascular risk factor.
Section 2 
The development of left ventricular hypertrophy
Embryonic development of the human myocardium, involves 
hyperplasia (growth through cell division) of undifferentiated myogenic 
cells, which later acquire the ability to synthesise myofibrillar proteins 
(55). Studies in the chick embryo, reveal continuing mitosis throughout 
fetal life with accumulation and longitudinal alignment of myofibrils until 
characteristic spindle shaped myocytes become recognisable (56).
After birth, mitotic activity in myocytes ceases, though myocardial 
connective tissue cells retain the capacity to divide (55). Normal postnatal 
cardiac development is therefore dependent on myocyte hypertrophy 
(growth through cell enlargement) and non-muscle cell hyperplasia (57). 
Increased collagen and fibrosis have also been observed in cases of 
"pathological" cardiac hypertrophy (58,59,60), and in extreme 
hypertrophy, division of ventricular muscle cells and their nuclei may 
occur (58). Although the mechanism of such cleavage is poorly 
understood, it is likely to represent splitting rather than DNA replication 
(61).
Left ventricular size is governed by the work undertaken, namely 
the generation of sufficient pressure within the ventricular cavity to expel 
blood. With a thin-walled sphere, Laplace has determined that the wall 
stress or tension (T) is related to the radius (R) of the sphere and to the 
pressure (P) within
22
T = p X R/2 
or P = T X 2/R
Because the left ventricle is a "truncated ellipsoid"(62), rather than 
a sphere, the amount of tension (T) that must be created at any one point 
to produce a given pressure (P) is expressed as
P= T (1 /R i + I/R 2 )
where R i and R2 are the principal radii of the curvature at that point.
This expression assumes R-) and R2 are large compared to 
ventricular wall thickness, but if the wall is thickened, the forces within it 
will not be evenly distributed. There is however evidence that tension is 
directly related to wall thickness (WT) (though the precise mathematical 
relationship is uncertain) (63).
P aT (WT/R1 + WT/R2 )
Thus, if the pressure increases and the left ventricular internal radii 
remain constant, wall thickness must increase to maintain wall tension. 
Conversely, if the pressure remains constant, but the ventricle dilates, an 
increase in wall thickness would also serve to sustain tension. Indeed, it 
has been suggested that the main purpose of cardiac hypertrophy is to 
preserve wall tension within normal limits (64).
Work (W) done by the heart, can be calculated from a derivation of 
the formula
W = F X d F - force
d - distance
In the circulatory system, pressure (P) is analogous to force per unit area
(a)
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p = F/a 
W  = P X a X d 
a X d = V V - volume
W = P X V
As ventricular pressure varies during ejection, the work done is 
expressed more accurately as
W  = fP dV
Since systolic aortic pressure closely approximates the integrated 
ventricular systolic curve, the stroke work (SW) of the ventricle is equal to 
the product of the mean systolic aortic pressure (MAP) and the stroke 
volume (SV).
W = MAP X SV
Both increased pressure and increased stroke volume (from ventricular 
dilatation) will therefore add to cardiac work load, which will in turn 
promote cardiac hypertrophy (65).
Section 3
Hypertrophy - pressure versus volume overload
The type of stress imposed upon the left ventricle determines the 
pattern of hypertrophy (66). When systolic pressure is raised, as a result 
of hypertension or aortic outflow obstruction, the left ventricular wall 
becomes uniformly thickened and chamber size remains unchanged - 
concentric hypertrophy (65). This effect is achieved through an initial 
though not sustained period of dilatation (67), a prompt increase in 
efficient myocardial protein synthesis (68,69), and possibly addition of 
new myofilaments leading to myofibrillar growth and even splitting (70).
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As a consequence, the pressure load is distributed over a larger number 
of contractile elements and the force per unit area remains constant.
In contrast, when the left ventricle is distended abnormally, as in 
chronic anaemia, arteriovenous shunting or states of fluid overload, the 
diastolic intraventricular volume increases. To maintain ventricular wall 
thickness, the muscle mass must also increase. Under such conditions of 
volume overload, the pattern of hypertrophy is uniform, but described as 
eccentric, because the heart is displaced to the left of the chest on x-ray. 
(64,66).
Chronic ventricular dilatation is associated with early enhanced 
myocardial protein synthesis (68,71), and in the model of the volume 
overloaded dog, progressive recruitment but not over-stretching of 
sarcomeres (72). This poses the question - how does the chronically 
dilated left ventricle expel an augmented stroke volume if not by a Frank- 
Starling response at sarcomere level? Although this mechanism may be 
important acutely, in chronic models, the generation of more sarcomeres 
permits normal performance over a greater circumference, in spite of the 
mechanical disadvantage conferred by dilatation.
Section 4
Determinants of left ventricular mass
Framingham data have pointed to a high prevalence of left 
ventricular hypertrophy in the community (53). With almost one fifth of the 
study population of 4976 participants affected, it was possible to 
undertake multivariate analyses to identify independent risk factors for left 
ventricular hypertrophy. Evidence from other population studies is also 
considered.
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2.4.1 Hypertension
The prevalence of left ventricular hypertrophy in hypertensive 
patients has been variously reported at 23 to 48% compared with a 
prevalence of 0  to 10% in normal subjects (73,74,75). Among employed 
patients with uncomplicated essential hypertension, the prevalence of 
hypertrophy was 1 2% in workers with borderline elevation of blood 
pressure (SBP 140-159 or DBP 90-94) and 20% In a group with more 
severe hypertension (SBP>160 and/or DBP>95) (76). This would suggest 
that the higher the blood pressure the greater the risk of left ventricular 
hypertrophy and early work supported such an hypothesis (77,78). Later 
studies then questioned the rather weak correlation between blood 
pressure and ventricular mass, particularly if blood pressure was 
measured by a doctor (75,79). When ambulatory blood pressure is 
monitored continuously, a significant relationship between left ventricular 
mass index and blood pressure (systolic or diastolic) may become 
apparent (80), but in one study this relationship held only in patients with 
normal ventricular mass (81). Variabilty of frequent blood pressure 
measurements might also be a predictor of left ventricular hypertrophy in 
patients treated for essential hypertension (82), but overall the correlation 
between blood pressure, however measured, and left ventricular mass is 
poor, suggesting factors other than blood pressure are important in the 
pathogenesis of cardiac hypertrophy.
Recently the conventional view that increased afterload from 
hypertension leads to cardiac hypertrophy has been challenged (83). 
Devereux has considered a growing body of evidence which shows that 
left ventricular hypertrophy may proceed and indeed predict high blood 
pressure and has suggested that increased muscle mass might be the 
primary abnormality responsible for exaggerated pressor responses (84).
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Without longitudinal studies which start in childhood and monitor blood 
pressure and left ventricular mass, this issue cannot be resolved.
2.4.2 Age
A positive correlation between left ventricular wall thickness and 
age has been demonstrated in men without hypertension or overt 
cardiovascular disease (85), and large population studies have 
consistently identified age as an independent determinant of cardiac size 
(53,76,86). Whether subtle and unrecognised changes in blood pressure 
explain these observations or whether they reflect reduced vascular 
compliance and hence increased peripheral vascular resistance is 
uncertain.
A syndrome of severe concentric cardiac hypertrophy in elderly, 
hypertensive, and often black patients has also been described (87). In 
this condition, named "hypertrophic cardiomyopathy of the elderly", the 
degree of hypertrophy exceeds expectation, given the level of blood 
pressure or evidence of other end-organ injury. Diastolic function is 
impaired and vasodilator drugs, prescribed because of heart failure at 
time of presentation, are tolerated poorly. The relative importance of age, 
hypertension and race in predisposing to this syndrome have not been 
defined.
2.4.3 Race
Several studies have suggested that black hypertensive patients 
matched for age, sex and arterial blood pressure, may have a higher 
prevalence of left ventricular hypertrophy than white patients (76,88,89). 
However the findings must be interpreted cautiously because they rely on
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the use of derived indices for muscle mass, whereas absolute 
measurements of wall thicknesses are no different between racial groups. 
Failure to take into account determinants of cardiac size other than simply 
age and arterial pressure could lead to spurious conclusions.
2.4.4 Body mass
It is recommended that echocardiographic measurements of left 
ventricular mass should be standardised by relating mass (g) to body 
size, preferably body surface area (g/m2) (90,91). Even with such 
correction, obesity in mildly hypertensive patients may be more important 
than blood pressure in determining cardiac size (92). Similarly, relative 
weight, as assessed by insurance companies, has also been shown to 
correlate better with left ventricular mass than does blood pressure (93). 
This might reflect the effects of increased cardiac output and augmented 
stroke volume on the left ventricle (94).
2.4.5 Exercise
Physical exertion imposes demands upon the heart, either in the 
form of pressure overload or volume overload. Pressure overload results 
from isometric exercise, such as weight-training, during which extreme 
rises in blood pressure can develop. Just as hypertension can cause 
concentric left ventricular hypertrophy (65), isometric exercise can 
produce considerable wall thickening (95), though this should be related 
to the accompanying increase in lean body mass.
Isotonic exercise or endurance training leads to periods of 
sustained increase in cardiac output (96). As might be expected, the left 
ventricular cavity expands (95), and ventricular wall thickness increases
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(97). Athletes, irrespective of the nature of their activity, manifest a 
number of rhythm disturbances more frequently than expected (98), of 
which a resting bradycardia is most common. Because the cardiac output 
in isotonic athletes at rest is normal, stroke volume must increase with 
training (99).
The long term effects of exercise-induced cardiac adaptation are 
not proven, but it has been suggested athletes may be at incresed risk of 
sudden death, particularly if performance enhancing drugs such as 
erythropoietin have been used (1 0 0 ).
2.4.6 Blood viscosity
It is recognised that haematocrit and whole blood viscosity are 
higher in hypertensive patients (1 0 1 ), and that even minimal elevation of 
blood pressure is associated with increased blood viscosity (1 0 2 ). 
Another factor also related to hyperviscosity, is cigarette smoking (103). 
Thus, the higher rates of cardiovascular morbidity and mortality reported 
in syndromes causing polycythaemia might be indirectly attributed to an 
excess of these risk factors (104,105,106).
Equally, haematocrit or whole blood viscosity might be 
cardiovascular risk factors, though conclusive evidence for this is not 
available. However whole blood viscosity has been shown to be more 
closely related to left ventricular hypertrophy than either systolic or 
diastolic blood pressure in patients with essential hypertension (107). 
Whether this is because cardiac hypertrophy and increased viscosity are 
both the effects of a common stimulus, or whether elevated viscosity is 
directly responsible for cardiac grov\4h is not known. Poiseuille's Law 
which relates vascular resistance directly to blood viscosity and indirectly 
to the fourth power of vessel radius indicates that an elevation in whole
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blood viscosity will result in increased total peripheral resistance, which in 
turn promotes cardiac hypertrophy. Alternatively, vasoconstriction could 
be the primary abnormality and by inducing haemoconcentration cause a 
rise in blood viscosity. Under conditions of vasoconstriction, contraction 
of plasma volume is accompanied by an increase in peripheral resistance 
(108), which is an additional stimulus to left ventricular hypertrophy.
2.4.7 Anaemia
While a raised haematocrit may influence the left ventricle, so too 
may a low haematocrit. The impact of chronic anaemia on the heart has 
been studied in greatest detail in sickle cell disease. Affected patients 
have been found to have enlarged ventricular cavities in both systole and 
diastole, greater stroke volume, increased septal width and greater left 
ventricular mass (109,110). Hypertrophy may not be associated with 
overt left ventricular dysfunction (109,110). However when the effects of 
altered loading conditions on systolic function are considered, impaired 
contractility can be demonstrated (1 1 1 ).
The cardiac changes in sickle disease have been attributed to long 
standing volume overload, and bear similarity to cardiac adaptations to 
increased cardiac output in animals with arteriovenous fistulae (1 1 2 ) and 
pregnant women (113). Restoration of normal circulating volume by 
repeated blood transfusion in children with sickle cell anaemia (114), 
shunt reversal in laboratory dogs (1 1 2 ), or delivery of pregnant women 
(113), result in the return of cardiac chamber size to normal and reduction 
in left ventricular mass.
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2.4.8 Sympathetic nervous system
Administration of exogenous catecholamines to experimental 
animals will induce hypertrophy of the myocardium (115), an effect 
sustained in the face of blood pressure control by alpha blockade (116). 
Furthermore, Yamori found that simultaneous beta adrenergic receptor 
blockade ameliorates the hypertrophic response to noradrenaline infusion 
(116). Later cell culture work challenged this evidence, by showing the 
increase in myocyte size to be an alpha adrenergic response (117). 
Nevertheless noradrenaline was seen to be "the myocardial hypertrophy 
hormone", capable of inducing myocardial cellular growth independently 
of changes in blood pressure (118).
Although findings in animal models may not apply to man, Dunn 
and Allen's observations on regression of left ventricular hypertrophy in 
hypertensive patients treated with beta blocking agents would indirectly 
support a role for the sympathetic nervous system in the pathogenesis of 
human cardiac hypertrophy (119,120).
2.4.9 Renin - angiotensin system
Angiotensin II infusion at a mildly pressor dose has been shown to 
produce an early increase in myocardial protein synthesis and ventricular 
weight (121). The advent of converting enzyme inhibitor drugs has 
therefore provided scope for further research in this area. Sen and 
colleagues (1 2 2 ) implicated the renin-angiotensin system in the 
pathogenesis of hypertrophy by reporting contrasting effects of 
antihypertensive agents on plasma and renal renin concentrations in 
relation to left ventricular mass: although minoxidil controlled blood 
pressure in spontaneously hypertensive rats, this was associated with
31
increased renin levels and ventricular weight remained constant. On the 
other hand, propranolol had less effect on blood pressure, but caused a 
fall in plasma renin and a reduction in left ventricular mass. With methyl 
dopa, a fall in both blood pressure and renin was accompanied by a 
decrease in cardiac mass. Further experiments by the same group In the 
same model, demonstrated that use of the converting enzyme inhibitor 
captopril (SQ 14225), prevented the development of hypertension and 
cardiac hypertrophy in young rats, and led to control of blood pressure 
and reversal of hypertrophy in older hypertensive rats (123).
In humans the potent hypotensive effects of converting enzyme 
inhibitors and beta adrenergic antagonists cannot be divorced from any 
possible direct action on the myocardium in attempting to explain the 
reduction in left ventricular mass that occurs with treatment (119,124).
2.4.10 Parathyroid hormone
An association between hypertension and hyperparathyroidism has 
long been recognised (125), but the relationship between cardiac 
hypertrophy and hyperparathyroidism was only first suggested when 
Symons et al. found elevated parathyroid hormone (PTH) levels in five of 
eighteen patients with hypertrophic cardiomyopathy and left ventricular 
hypertrophy in all but one of sixteen patients with primary 
hyperparathyroidism (126). As hypertrophy was not identified in patients 
with hypercalcaemia for other reasons (126), a PTH induced increase in 
transmembrane calcium flux, was the mechanism proposed (127).
This work, as well as reports of high levels of free intracellular 
calcium in patients with essential hypertension (128), stimulated 
Dominiczak and colleagues to study platelet free calcium in 
hyperparathyroidism, relating calcium levels to arterial blood pressure
32
and left ventricular mass (129). Although her subjects with primary 
hyperparathyroidism had both significantly elevated blood pressure 
(compared to controls) and hypercalcaemia, their intracellular free 
calcium levels were lower than expected, and several explanations were 
offered. Of special interest however, was that left ventricular mass index 
in the primary hyperparathyroid group was higher than in control subjects 
matched for age, sex and blood pressure and moreover fell slightly after 
parathyroidectomy, despite continuing high blood pressure. These 
findings support the view that parathyroid hormone has an effect on the 
left ventricle, at least in primary hyperparathyroidism.
2.4.11 Other endocrine disorders
Cardiac hypertrophy has also been described in 
phaeochromocytoma, acromegaly and hyperthyroidism (130). In the first 
two conditions, hypertension could be a contributing factor, and in 
hyperthyroidism, volume overload. In addition, catecholamines (115) and 
thyroxine (131) produce hypertrophy in experimental animals, and it is 
likely that specific hormonal effects are also important.
Section 6
Physiological or pathological hypertrophy?
The development of hypertrophy in response to haemodynamic 
loading of the left ventricle appears to be a useful physiological 
adaptation, as it enables the heart to undertake increased work without 
compromising function. However, pressure and volume overload are not 
uncommonly associated with cardiac failure, and it has been suggested
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that cardiac hypertrophy facilitates normal function only when stresses 
are not sudden, severe or sustained (132,133).
Whether, or at which point, physiological hypertrophy becomes 
pathological on account of impaired function is difficult to determine, but 
aging and coronary vessel disease predispose. Diagnosing dysfunction in 
humans can be awkward because measures of systolic function are 
influenced by volume loading, and simple and reliable methods of 
assessing diastolic function are not available.
Nevertheless, Gaasch has evaluated use of the ratio of diastolic 
left ventricular radius to wall thickness, as a means of differentiating 
between physiological, or compensated hypertrophy on the one hand, 
and on the other, pathological, inadequate or inappropriate, hypertrophy 
(134).
Section 6
Effects of left ventricular hypertrophy
The increased morbidity and mortality associated with left 
ventricular hypertrophy can be attributed to angina pectoris, non-fatal and 
fatal myocardial infarction, congestive cardiac failure, and sudden death. 
From ante- and post-mortem studies of human hearts and experiments in 
animals, a number of mechanisms are thought to be responsible.
2.6.1 Myocardial ischaemia and hypertrophy
Volume or pressure loading of the left ventricle results in increased 
oxygen uptake and myocardial oxygen requirements are uniformly related 
to wall stress (135). Once hypertrophy is established, the greater oxygen 
requirements are maintained because of greater metabolic activity, in
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part these demands can be met through increased oxygen extraction from 
capillary blood by the hypertrophied myocardium (136). In addition, blood 
flow may be augmented, as ventricular growth is accompanied by a 
significant proliferation of capillaries (137), though the overall density of 
capillaries is still diminished (138). Blood flow studies indicate that 
endocardial perfusion in hypertrophioed dog hearts is reduced in 
comparison with normal hearts and stress in the form of ischaemia 
induced vasodilatation further accentuates the regional hypoperfusion
(139). The suspicion that this subendocardial area might be vulnerable to 
ischaemia is supported by the demonstration of subendocardial fibrosis In 
patients who died with hypertension (60) or aortic stenosis or coarctation
(140). Indeed, the degree of scarring of the endocardium correlates 
directly with heart weight (141) and the intrinsically high oxygen 
consumption in this part of the heart may amplify susceptablity to hypoxic 
damage (142) and explain the non-uniform distribution of scar tissue.
Blood supply may be further compromised in the presence of 
coronary artery disease, which frequently coexists with left ventricular 
hypertrophy (143,144), perhaps because atherogenesis and hypertrophy 
share several pathogenetic factors. While myocardial infarction may 
result in compensatory hypertrophy, there is no evidence that left 
ventricular hypertrophy per se causes major coronary vessel disease. 
However significant narrowing of small intramyocardial arteries from 
intimai proliferation has been reported in hypertensive hearts (145). Such 
changes could explain the diminished coronary flow reserve described in 
patients who have cardiac hypertrophy and typical anginal pectoris, yet 
angiographically normal epicardial coronary arteries. (146).
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2.6.2 Systolic function of the left ventricle
Early studies which described normal or enhanced myocardial 
contractility in animals (147), papillary muscle preparations (148), and 
humans with cardiac hypertrophy have been contradicted (149) and 
criticised on a number of points. First, it is important to relate tension to 
unit area of ventricular wall (150). Second, experimental techniques used 
to induce cardiac hypertrophy such as banding of the aorta or pulmonary 
artery can alter ventricular function by causing myocardial fibrosis (151) 
and third the timing of assessment of systolic function may affect results 
(152). In addition, alterations in both preload and afterload can influence 
widely used measures of systolic function, such as ejection fraction, 
fractional shortening and velocity of circumferential fibre shortening, 
independently of changes in muscle function. Left ventricular end-diastolic 
diameter is dependent on left ventricular end-diastolic pressure or 
preload, and end-systolic volume will be determined in part by end- 
systolic force or afterload. As a consequence, the value of accepted 
indices of contractility may be limited, at least in conditions of volume 
overload, valvular dysfunction or hypertension. However the end-systolic 
volume is not dependent on the initial ventricular volume (153) and the 
relationship between end-systolic length (or volume) and end-systolic 
force (or pressure) is linear (154). Therefore it has been suggested that 
the slope of the end-systolic afterload plotted against end-systolic volume 
will vary with contractile function rather than load and that the study of this 
relationship under varying loading conditions offers the most precise 
method of assessing muscle function (155,156,157). In states of cardiac 
hypertrophy, wall stress is preferred to pressure as a measure of 
afterload because it allows for left ventricular thickness (158). Studies of 
left ventricular fractional shortening and systolic wall stresses in
36
hypertrophied hearts have endorsed these findings and suggested that 
cardiac performance is initially maintained, but declines with progressive 
rise in afterload, particularly when ventricular dilatation is a feature 
(159,160).
2.6.3 Diastolic function of the ieft ventricle
Normal diastolic function implies complete filling of the left 
ventricle during diastole which depends on full relaxation of myocardial 
fibres and the elastic recoil of the ventricular wall. The "relaxation" is in 
fact an active process of calcium uptake by the sarcoplasmic reticulum 
and hydrolysis of ATP (161). Thereafter opening of the mitral valve 
facilitates diastolic filling of the left ventricle, the result of both the 
pressure gradient between the left atrial and ventricular chambers and the 
inherent passive elastic properties of the left ventricle. Only at rapid heart 
rates, does the atrial contraction contribute to diastolic filling in health.
Abnormal left ventricular diastolic function, in the presence of 
normal systolic function has been described in hypertensive patients 
(162), even before cardiac hypertrophy has developed and has been 
attributed to altered collagen composition within the myocardium 
impeding elasticity (163). Ischaemia may further compromise diastolic 
relaxation either by reducing the potential for oxidative phosphorylation 
(164) or causing fibrosis. Amyloid deposition in older hearts also impairs 
diastolic function.
In conditions of reduced diastolic compliance, atrial systole is 
important in maintaining ventricular filling. This has been demonstrated by 
doppler measurement of the peak early flow velocity through the mitral 
valve (E wave) and the maximal late flow velocity generated by atrial 
contraction (A wave) (165). In hypertrophied hearts with diastolic
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dysfunction the ratio of E to A is reduced, although the index must be 
interpreted cautiously as transmitral flow may be influenced by 
haemodynamic loading (166,167). However, radionuclide 
ventriculography in the study of movement of technetium-labelled red 
cells has verified the prolongation of ventricular filling in hypertensive 
subjects (168).
2.6.4 Sudden death and left ventricular 
hypertrophy
In the Framingham Study sudden death was was first linked with 
left ventricular hypertrophy (46) and a later publication reported a five fold 
increase in people with electrocardiographic left ventricular hypertrophy 
(169). Post mortem studies have confirmed hypertrophy to be a common 
finding in such victims, although an excess of coronary artery disease 
does not appear to be present (170). McLenachan et al have 
demonstrated that complex ventricular arrhythmias occur more frequently 
in hypertensive patients if echocardiographic left ventricular hypertrophy 
Is present and are not explained by poorer blood pressure control, 
cigarette consumption, diuretic therapy or hypokalaemia. (171). 
Arrhythmias are now widely believed to be responsible for sudden death 
in patients with cardiac hypertrophy.
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Chapter 3
THE LEFT VENTRICLE IN CHRONIC RENAL FAILURE
While vascular disease accounts for considerable morbidity and 
mortality among patients with chronic renal failure, a growing body of 
evidence suggests that ventricular disease may also play an important 
and hitherto underestimated role.
Section 1
The heart and renal disease - in the past
After Richard Bright's early observations of cardiac hypertrophy in 
patients with nephritis, several of his contemporaries also documented 
the association (172). However, the nature of the relationship between 
cardiac and renal disease was not examined in detail until Saundby 
published his views on the role of hypertension later in the nineteeth 
century (173). In 1910, Oertel reiterated similar theories (174), then 
Evans, in a pathological study of arteriosclerosis in chronic renal disease, 
implicated raised blood pressure in the pathogenesis of both vascular 
lesions and ventricular hypertrophy. Evans also concluded that with few 
exceptions chronic renal disease caused cardiac hypertrophy, and was 
the commonest cause in patients under the age of thirty-five years without 
heart or lung disease (175). In both this and Solomon's post-mortem 
study of uraemic hearts (176), atheroma of the coronary arteries was a 
relatively infrequent finding and bore no relationship to heart weight.
Richter and O'Hare who had the opportunity to follow sixty-six 
patients with chronic glomerulonephritis in life, observed that cardiac 
symptoms rarely occured until the year proceeding death (177). The
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majority of deaths resulted from uraemia and pericarditis was a common 
post-mortem finding in 48 percent, clinical signs having been present in 
most in the late pre-terminal phase. Half of the of patients who died of 
uraemia had increased heart weights, mainly due to the left ventricle, and 
even hearts of normal weights still exhibited left ventricular hypertrophy. 
The incidence of coronary artery disease in these patients equalled that 
reported in non-hypertensive heart disease, in spite of a history of 
hypertension in almost all.
As well as hypertrophy, Gouley described focal areas of 
myocardial degeneration in the hearts of patients suffering chronic 
glomerulonephritis and hypertension and suggested this might be the 
result of "uraemic intoxication" (178). Solomon also commented upon 
various microscopic cardiac lesions in other terminal renal diseases 
(176). These, he described as widespread areas of fatty degeneration 
and points of miliary myocardial necrosis, often associated with acute 
interstitial myocarditis. In his report of fifty patients, twenty-six had clinical 
cardiac failure, and twenty-five of these, focal lesions of the myocardial 
fibres. His conclusion however was that there was no specific cardiac 
lesion which could be considered characteristic of the uraemic state. 
Raab noted similar post-mortem appearances in uraemic hearts and from 
further animal experiments in which the cardiac effects of human uraemic 
sera were tested, deduced that catechol-like compounds were 
responsible for depressed cardiac function (179)
At that time any influence of left ventricular hypertrophy on the 
electrocardiogram was ignored, although characteristic features of 
hyperkalaemia (180) and repolarisation changes which would be 
compatible with left ventricular hypertrophy and strain pattern (179) were 
recognised. Much of the subsequent work which has added to the 
understanding of ventricular disease in renal failure stemmed from
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studies in hypertension, because with the development of dialysis and 
transplantation, nephrological attention turned away from pathological 
review towards improving survival in uraemia by the "replacement" of 
renal function.
Section 2
The heart and renal disease - in the present
During the past thirty years both the potential and limitations of 
renal replacement therapy have been recognised. With dialysis and 
frequently transplantation, only "partial replacement" is achieved and 
perhaps this is one of the reasons why such high mortality rates in end- 
stage renal disease are observed. However identifying specific factors 
which explain the mortality and in particular the high incidence of 
cardiovascular complications in uraemia, has proved difficult. The 
widespread assumption that risks which predispose the general 
population to cardiovascular disease apply in renal failure is largely 
unsupported, but would seem reasonable.
From the few studies which have attempted to recognise predictors 
of survival in patients with end-stage renal disease at the start of their 
renal replacement therapy, age, duration of diabetes, left ventricular 
failure (181) and left ventricular hypertrophy (48) have emerged as 
definite risk factors. Symptoms of left heart failure appear to be more 
important than symptoms of ischaemic heart disease in determining 
outcome (181 ), and the influence of increased left ventricular mass 
persists when adjusted for age, coronary heart disease, diabetes and 
systolic blood pressure (48). As both the size and function of the left 
ventricle may have prognostic significance, the prevalence and 
pathophysiology of ventricular disease in uraemia deserve attention.
41
3.2.1 Cardiac morphology and function in chronicrenai failure
Many of the pathologists' findings (Section 1) have been identified 
in patients with renal impairment, by means of non-invasive 
investigations. M-mode echocardiography has revealed the presence of 
pericardial effusions and thickening, left ventricular hypertrophy and 
dilatation, and valvular calcification and vegetations in symptomatic 
patients with chronic renal failure in the pre-dialysis period (182). It has 
also proven valuable in assessing ventricular function in such patients 
(183). However, more commonly studies have been undertaken in 
patients with end-stage renal failure after the start of dialysis when aortic, 
left atrial, valvular, and a spectrum of ventricular abnormalities may be 
present (184). As the techniques of echocardiography and radionuclide 
imaging have developed, knowledge of the structure and function of the 
left ventricle in uraemia has grown.
Numerous studies, employing various echocardiographic ( 184, 
185,186,187,188,189,190,191,192,193,194,195,196,197,198,199, 
200,201,202,203,204,205,206) and angiographic (207,208,209) methods 
have identified left ventricular hypertrophy in dialysis patients. Reports of 
its prevalence range between 42% (43) and 90% (39), depending upon 
the technique used, the method of determining left ventricular mass, and 
the criteria defining left ventricular hypertrophy. The timing of the 
assessment is also important as fewer patients in the pre-dialysis phase 
seem to be affected (182) and hypertrophy may increase with time on 
dialysis (chapter 4). Hypertrophy may have a higher prevalence among 
peritoneal dialysis patients compared with those on haemodialysis, 
though the study populations are small (203). Increased work of the heart 
is thought to be responsible (207), though a number of other risk factors
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for left ventricular hypertrophy in patients with end-stage renal disease 
have been identified by means of multiple regression analyses: age 
(203), hypertension (Harnett), high serum alkaline phosphatase possibly 
reflecting hyperparathyroidism (203) may contribute. Anaemia (208) and 
excessive interdialytic weight gain (190) perhaps leading to raised atrial 
natriuretic peptide levels (2 0 0 ) have also been suggested as causes.
The pattern of hypertrophy may be concentric or less commonly 
asymmetric affecting the septum (190), although there is a tendency to 
overestimate the thickness of the septum if an oblique echocardiographic 
cut without the guidance of a two-dimensional scan is undertaken (206, 
204). Bernardi has postulated that asymmetric septal hypertrophy is the 
earliest sign of myocardial involvement in uraemia (204) and may result 
from sympathetic overactivity as assessed by plasma adrenaline and 
noradrenaline levels (205). Catecholamines have also been weakly linked 
to myocardial dysfunction in dialysis patients (187).
Left ventricular hypertrophy in hypertensive populations (171) and 
people with hypertrophic cardiomyopathy (2 1 0 ) has been associated with 
an increased risk of serious ventricular arrhythmias. Patients with end- 
stage renal disease on haemodialysis are also undoubtedly at risk (2 1 1 , 
212, 213, 189, 184), despite contradictory negative findings in studies too 
small to draw valid conclusions (214, 215). The association between such 
arrhythmias and ventricular hypertrophy in end-stage renal disease 
however is less well defined (2 1 2 ), and it has been suggested that left 
ventricular dysfunction is a more potent risk factor (211, 184).
Patients with cardiac hypertrophy have been reported to have a 
greater incidence of coronary vessel disease, than those without (209) 
and this may in part explain the depressed myocardial function frequently 
observed in association with hypertrophy or arrhythmias.
43
Congestive cardiac failure has been described in up to ten percent 
of non-diabetic dialysis patients, half of whom have a hypertrophic type of 
cardiomyopathy and the other half a dilated picture (199) However, 
caution is required when interpreting studies reporting cardiac dysfunction 
in dialysis patients (216,185,187,188,217,218,191,219,220,193, 
194,221,196,203,199,202,222) because of the effects of overhydration on 
preload and afterload and hence the assessment of myocardial 
contractility. Nevertheless, cardiac function appears to be abnormal in a 
significant proportion of patients at dry weight or after ultrafiltration, 
suggesting that other factors may influence ventricular performance.
Section 3
Ventricular influences in end-stage renal disease
As previously described (Chapter 2.2), the left ventricle 
hypertrophies in response to pressure or volume overload, both of which 
can ultimately cause left ventricular dysfunction. Not only are many of the 
factors (2.4.1 - 2.4.11) which produce such overload typically present in 
end-stage renal disease, but they can be of a marked degree and 
frequently occur in combination. In addition, other "ventriculopathic" 
factors peculiar to uraemia may contribute to cardiac hypertrophy. With 
replacement of renal function, the left ventricle may be exposed to further 
risks, such as creation of vessel access, aluminium accumulation from 
phosphate binding agents and dialysate. These and other "therapeutic" 
risks will be discussed separately (chapter 4 ).
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3.3.1 Uraemia
Early haemodynamic studies of patients with chronic renal failure 
consistently identified an increased plasma volume (223, 224), though 
data on cardiac output conflicted. Del Greco and colleagues found 
cardiac output in patients with uraemia to be increased when signs of 
circulatory congestion were absent, but to be decreased in the presence 
of clinical congestive cardiac failure (223). His two groups however were 
not strictly comparable because of better renal function and higher 
haematocrits in the non-congested group. Gibson, who measured right 
heart pressures in patients with renal failure and acute pulmonary 
oedema found them to be normal or only moderately elevated, and 
suggested that increased pulmonary capillary permeability led to the 
development of pulmonary oedema in uraemia (224). Debate centred 
around the relative contributions of haemodynamic, myocardial and 
metabolic abnormalities in the pathogenesis of congestive cardiac failure 
and even by 1975 it was still unclear as to whether uraemia caused a 
specific cardiomyopathy (225). Drüeke, in a small study of haemodialysis 
patients was convinced of the existance of uraemic cardiomyopathy 
(216), yet Lewis found no evidence of such a phenomenon in patients in 
the predialysis phase unless severe fluid overload was present (183). 
lanhez observing resolution of cardiac failure after renal transplantation 
also suggested uraemia had a negatively inotropic effect, but he 
disregarded the concomitant improvement in anaemia and 
hyperparathyroidism (226). Stronger evidence came from animal 
experiments.
Penpargkul in a study of isolated hearts from rats with and without 
acute and chronic uraemia, found that hearts from animals with recent
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bilateral nephrectomies performed normally, as those from sham 
operated controls, while organs from a chronic renal failure subtotal 
nephrectomy model, exhibited enhanced contractility, coronary flow and 
myocardial oxygen consumption (227). The uraemia however was of 
relatively short duration, the hearts were not perfused with uraemic 
compounds and surprisingly the chronically uraemic hearts were no 
heavier, although did comprise a greater fraction of total body weight 
which was reduced in the uraemic animals. Using the same isolated heart 
model but this time from normal rats perfused with solution containing 
urea and other uraemic toxins, Scheuer and Stezoski, found that the rate 
of rise of left ventricular pressure was reduced in the presence of urea at 
varying concentrations (228). Such depressed contractility occured in 
spite of a raised end-diastolic pressure in the animals exposed to uraemic 
compounds, suggesting attenuation of the normal Frank-Starling effect.
As coronary flow rates were lower with uraemic perfusate, diminished 
oxygen delivery was proposed as the mechanism. However in this 
experiment only the acute effects of uraemic perfusate on normal rat 
hearts were studied, and the concentrations of urea exceeded those 
found in end-stage renal failure. Similar results were obtained in a study 
of short-term exposure of normal guinea pig hearts to urea concentrations 
in a more realistic uraemic range (229).
In a study of longer term chronic renal failure in rats, Rhodes et al 
noted the development of myocardial hypertrophy, focal myocardial 
necrosis and interstitial fibrosis, but did not undertake functional studies. 
(230). Vascular lesions, myocardial and aortic calcification, and increased 
vascular permeability in the pericardium were also features.
However, the Heidelberg group were able to examine the 
development of myocardial fibrosis in uraemic rats in greater detail and 
also determine the effect of the converting enzyme inhibitor ramipril (231).
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Heart weight was greater in a uraemic group compared to sham-operated 
controls, and by light and electron microscopy both the number and 
volume of interstitial cells were increased, suggesting that the cardiac 
hypertrophy was not myocardial. As interstitial cell nuclear size was also 
greater in uraemic animals these cells were assumed to be in an 
activated state. Non-cellular interstitial tissue was also more abundant 
without an apparent increase in vascular permeability, and fibrosis was 
shown to ultimately occur. The absence of myocardial necrosis led the 
authors to conclude that fibrosis was of the non-replacement type, thus 
challenging earlier views on ischaemic myocardial cell injury in cardiac 
hypertrophy. They also postulated that interstitial fibrosis in uraemia 
might result in reduced cardiac compliance or predispose to disturbed 
electrical conduction, re-entry and cardiac arrhythmias. Finally, an 
increased interstitial volume in ramipril treated rats, suggested that 
hypertension was not the mechanism responsible. The same group had 
previously established that heart weight in rats with renal insuffiency was 
increased despite normalisation of blood pressure with alpha-1-receptor 
or beta-1-receptor blockers, (232).
3.3.2 Hypertension
Further haemodynamic studies in uraemic patients attempted to 
define the effects of hypertension. Kim and colleagues confirmed earlier 
reports of raised cardiac indices, heart rates and systolic blood pressures 
in end-stage renal disease (233). However he demonstrated that derived 
measures of total peripheral vascular resistance were higher in 
hypertensive uraemic patients compared to normotensive uraemic 
patients and furthermore, that bilateral nephrectomy in the hypertensive 
patients resulted in a reduction in peripheral resistance and blood
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pressure. This raised the possibility that a vasopressor substance of renal 
origin might cause renal hypertension, a theory which was later to be 
verified by recognition of the renin-angiotensin system.
In addressing the question of whether renovascular hypertension 
had more deleterious cardiac effects than essential hypertension, Vensel 
found a greater degree of left ventricular dilatation in patients with 
renovascular disease accompanied by reduced fractional shortening, and 
assymetric septal hypertrophy (234). Neither the creatinine 
measurements of patients with essential hypertension, nor haemoglobin 
concentrations for the whole group were quoted, and renovascular 
patients had higher systolic blood pressures. It is therefore difficult to 
directly compare the different groups or conclude about the impact of this 
form of secondary hypertension on the heart although there was a 
suggestion that the cardiac effects of renovascular disease were more 
adverse. Furthermore, these patients had only a moderate degree of 
renal impairment, and were still far from requiring dialysis.
Studies of patients who have reached end-stage renal failure and 
started on renal replacement therapy reveal that the commonest 
echocardiographic abnormalities are of enlargement of the cardiac 
chambers coupled with a moderate increase in left ventricular mass (235) 
To what extent hypertension contributes to these findings is unclear, 
although the correlation between arterial hypertension and cardiac 
hypertrophy has frequently been reported as weak (232,235). Some 
authors have suggested that the degree of hypertrophy is inappropriately 
low for the level of the blood pressure and chamber dilatation, and that 
the left ventricular hypertrophy of end-stage renal disease is "inadequate" 
(235). In normal subjects there is a constant relationship between arterial 
pressure and left ventricular mass-to-volume ratio ( 1 3 4  ), which is 
absent in dialysed uraemic patients. However few investigators of
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uraemic patients have measured blood pressure continuously, and where 
this technique has been employed, data are scarce though said on trust 
to show that blood pressure is volume dependent (236). One of the great 
difficulties in studying such populations is differentiating between genuine 
hypertension and fluid overload, and the ideal timing of assessment in 
relation to haemodialysis is not clear.
Cochi measured blood pressure and left ventricular size before and 
after haemodialysis, in groups of patients whose background blood 
pressure control varied and found no significant differences between 
normotensives' and hypertensives' left ventricular dimensions (237).
There was however a tendency for wall thickness to increase with blood 
pressure, and for left ventricular diameter to rise with greater interdialyctic 
weight gains. In contrast, Voogd did find a correlation between left 
ventricular hypertrophy and systolic and diastolic blood pressure, but only 
in anephric patients (238). He also attributed paradoxical increases in left 
ventricular thickness after the inception of dialysis to fluid excess.
By submitting thirty-five patients with chronic renal impairment and 
ten control subjects to volume expansion with one litre of saline, and 
monitoring their right heart pressures and in twelve left heart pressures, 
Jahn and colleagues found a positive correlation between cardiac index 
and plasma creatinine in the majority (239). However the correlation 
between cardiac index and haematocrit was stronger and increased 
further after saline infusion. Cardiac function as assessed by relating 
volume expansion induced changes in stroke index to changes in 
pulmonary capillary wedge pressure varied greatly, but decreased with 
the severity of renal failure, implying reduced diastolic compliance. On 
the other hand, systolic function, quantified in a complex fashion by 
simultaneous left ventricular pressure recording and echocardiographic 
derivation of left ventricular volume, was normal in six patients in whom
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satisfactory measurements could be achieved. No comment was made 
about cardiac mass in this study. Golf also examined the effects of 
overhydration on cardiac function in haemodialysis patients: clinical 
congestive cardiac failure developed only In fluid overloaded patients 
whose hearts were additionally stressed by exercise and anaemia (240).
3.3.3 Anaemia
Subjective symptoms of dyspnoea and fatigue in chronic renal 
disease worsen with anaemia, and objectively the degree of impairment 
of aerobic and anaerobic capacity correlate directly with the severity of 
anaemia (241). However the precise cardiac effects of anaemia are less 
well understood. In anaemic subjects with normal renal function, cardiac 
output at rest is almost always elevated, when the haemoglobin level falls 
as far as 7g/dl (242, 243, 244, 245), but may be within normal limits in 
less severe anaemia (244). This rise is mainly the result of an increased 
stroke volume rather than increased heart rate, but it is blunted by age 
(245). An exaggerated increase in stroke volume and cardiac output also 
occurs in response to aerobic exercise in anaemic subjects (244, 246, 
243) when compared to healthy controls and exercise may unveil altered 
haemodynamics in less severe degrees of anaemia (244).
Shorter circulatory times have been demonstrated in anaemic 
states (246, 245), though venous tone and intravascular volume will also 
Influence the duration. Right heart pressure (243) and pulmonary arterial 
wedge pressure (243, 247) are normal, unless other cardiopulmonary 
disease is present. While plasma volume tends to be increased in 
anaemia (245), the total blood volume is often reduced because of 
diminished red cell mass (244). This, together with Fowlers study of 
anaemic and hypovolaemic dogs capable of generating high cardiac
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outputs (248), suggests that increased preload is not the cause of 
augnnented stroke volume.
The explanation therefore lies in the alteration of afterload, either 
through a change in peripheral vascular resistance or blood viscosity. 
Graettinger introduced the idea that reduced systemic vascular resistance 
was responsible for the elevation in cardiac output (244), though did not 
describe the mechanism. Duke and Abelmann confirmed this view by 
reversing the high output in anaemic patients with orthostatic stress or the 
vasoconstrictor drug methoxamine (245). Relative hypoxia in anaemic 
patients seemed a likely stimulus to vasodilatation (249).
Murray and Escobar disagreed. In their study of the effects of 
reducing the oxygen carrying capacity of the blood, with or without a 
reduction in viscosity, on cardiac output in dogs they argued that reduced 
whole blood viscosity was an equally if not more important contributor 
(250). By administering exchange transfusions of whole blood, 
methaemoglobin containing blood, plasma or dextran, they found the 
greatest increase in cardiac output to occur in animals subjected to both a 
lowering of oxygen carrying capacity and of whole blood viscosity. An 
inverse relationship between cardiac output and whole blood viscosity 
was supported by Weber's study of polycythaemic patients treated with 
radioactive phosphorous (251).
However Glick et al reported that the increase in cardiac output in 
anaemia was not entirely attributable to reduced whole blood viscosity, 
and that an intact autonomic nervous sytem was necessary for maximal 
elevation of cardiac output to develop in some, but not all, laboratory 
animals (252). Escobar also presented evidence of an enhanced 
ventricular contractility in acutely anaemic yet normovolaemic dogs, 
though was unable to conclude about the effects of sympathetic beta 
blockade because of the possibility of a direct cardiodepressant action of
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propranolol (253). In further experiments using dogs with acute 
isovolaemic anaemia, improved ventricular performance at rest and 
during exercise was ascribed to increased sympathetic stimulation and 
hence myocardial contractility (254). Whether a rise in left ventricular 
diastolic volume leading to a Frank-Starling inotropic effect can be 
excluded In these studies is unclear, as is their relevence to the 
chronically anaemic state in man.
Are the cardiovascular responses to anaemia in chronic renal 
failure different? The pioneering study of Neff et al which was designed to 
determine whether increased cardiac output in anaemic haemodialysis 
patients caused hypertension, provided some answers (255). As others 
have also described (256, 247), cardiac output in the study population of 
forty haemodialysis patients was increased, with an inverse correlation 
between cardiac index and haematocrit apparent. Although the mean 
blood pressure of the group was elevated, derived peripheral vascular 
resistance was normal. The authors hypothesis that increased cardiac 
output is causally related to hypertension was refuted because the 
cardiac indices of hypertensive patients were no higher than those of 
normotensives. Furthermore, correction of anaemia by transfusion of red 
cells in six patients led to reduction in cardiac output in five, but a rise in 
diastolic and mean blood pressure. It was suggested that transfusion 
abolished the hypoxic vasodilatation of anaemia and resulted in a rise in 
arteriolar resistance and blood pressure. Neff also proposed that the 
anaemia of chronic renal failure might even protect patients from the 
adverse effects of severe hypertension (255).
However evidence from Silberberg challenges such a view. In a 
study of 78 dialysis patients, he found a significant relationship existed 
between anaemia and echocardiographic left ventricular hypertrophy 
(208). Using the method of Devereux and Reicheck to determine left
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ventricular mass (LVM), the mean LVM index ranged from 120±8g/m 2 of 
the patient group in the highest quartile of haemoglobin, to 158±6g/m 2 of 
the group in the lowermost quartile of haemoglobin. Although, the 
outcome of these anaemic patients was not described, in a later paper, 
Silberberg demonstrated that left ventricular hypertrophy was an 
independent determinant of survival in end-stage renal disease (48), 
thereby indirectly associating anaemia with an increased risk of mortality. 
However, the pathogenesis of ventricular hypertrophy is likely to be 
multifactorial, and avoidance of anaemia by transfusion of uraemic rats 
does not prevent an increase in heart weight (232).
3.3.4 Hyperparathyroidism
One of the complications of chronic renal failure, arising as a result 
of phosphate retention and relative deficiency of 1,25-dihydroxy-vitamin 
D3 , is secondary hyperparathyroidism. As a consequence of increased 
parathyroid hormone (PTH) secretion, bone resorption and turnover Is 
stimulated and serum calcium levels rise. In the presence of high serum 
phosphate concentrations, deposition of calcium phosphate in soft tissues 
and blood vessels is favoured.
Milligan, in a comprehensive review of metastatic calcification, 
gathered reports of 23 patients with chronic renal disease in a predialysis 
era, who at post mortem were found to have widespread tissue 
calcification (257). Eleven had cardiac calcification, most marked in the 
left ventricle, but not all had parathyroid hyperplasia. Terman suggested 
that moderate to severe cardiac calcification may result in disturbances of 
conduction such as varying degrees of heart block (258). Others have 
reported marked and rapidly progressive calcification of the left-sided 
heart valves, particularly the mitral, sufficiently severe to cause functional
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impairment (259, 260). In a larger echocardiographic study of 87 older 
haemodialysis patients, Maher and colleagues found calcification of the 
aortic valve in 24 (28%) patients, and of the mitral annulus in 31 (36%)
(261). Six patients, five with aortic disease had significant valvular 
stenoses, although clinical murmurs were a poor guide to their presence. 
The changes were attributed to abnormal calcium and phosphate 
metabolism, as the calcium-phosphate products in affected patients 
tended to be higher, and also to increased mechanical stress upon the 
valves. The risk of infective endocarditis in such patients is not known.
Myocardial calcium, as assesed by the technique of energy 
subtraction radiology, was estimated and related to echocardiographic 
left ventricular ejection fraction in 43 dialysis patients and 32 controls
(262). The myocardial calcium content was higher in uraemic patients 
and was significantly and inversely related to ejection fraction, thus 
Implying calcium depostion has a cardiodepressant effect. Ejection 
fraction was also directly related to PTH concentration, but there was no 
association between myocardial calcium content and PTH. Multiple 
regression analyses revealed positive correlations between myocardial 
calcium content and calcium-phosphorous product, vascular calcification, 
colour (black) and previous parathyroidectomy.
Although these studies suggest a role for PTH in the pathogenesis 
of uraemic left ventricular disease, its specific effects have only been 
studied in animal experiments. Bogin et al examined the responses of 
cultured rat heart cells to intact PTH, amino-terminal (1-34) and carboxy- 
terminal (53-84) PTH (263). Only the intact and N-terminal molecules 
produced responses; an immediate and sustained rise in heart rate and 
early cell death.These actions were assumed to be mediated through 
calcium entry into the cell because they required calcium and could be 
mimicked by a calcium ionophore and blocked by the calcium antagonist
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verapamil. Furthermore exposure of the cultured cells to uraemic rat sera 
caused similar effects only if the donor animals had parathyroid tissue
(263). Katoh also documented the positive intropic action of PTH (264), 
but later work from Massry's group was contradictory, as it demonstrated 
calcium dependent inhibition of cardiac mitochondrial respiration by 
chronic PTH administration in rats, leading eventually to a decrease in 
cardiac output (265).
Kraikipanitch demonstrated that both the calcium content of the 
myocardium and muscle mass are increased in uraemic dogs retaining 
pararthyroid tissue, and similar findings have been reported in rats (266, 
232). However the development of cardiac hypertrophy is not prevented 
by parathyroidectomy before the induction of renal failure and is therefore 
not dependent on PTH alone (232). Nor is the rise in heart calcium in 
renal failure, solely mediated by PTH (232).
Some authors have suggested that accumulation of calcium in 
myocardial cells might be harmful because catecholamine stimulated 
calcium entry can cause necrosis (267). There is no direct evidence of 
such an effect in uraemia, although early studies did identify PTH 
dependent calcium deposits in the myocardium and coronary arteries of 
rats rendered uraemic (268). It is more likely that calcium acts as an early 
stimulus to DNA synthesis and cell growth (269). In the Syrian hamster 
model of hypertrophic cardiomyopathy, myocytic calcium levels are 
elevated (270), and development of the condition is retarded by treatment 
with the calcium channel blocker, verapamil (270). In contrast, 
administration of a calcium ionophore to pregnant rats results in cardiac 
hypertrophy characterised by myofibrillar disarray (127).
PTH has other effects which could influence left ventricular 
morphology and function: It has vasodilator properties and causes 
hypotension in a dose dependent fashion when injected intravenously into
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rats and dogs (271). While many visceral vascular beds including the 
heart and kidney are affected, skeletal muscle is not. Intracellular cAMP 
is involved and preliminary evidence points to blockade of calcium entry 
into vascular smooth muscle as the mechanism (272). The 
cycloxygenase inhibitor, indomethacin attenuates this hypotensive 
response suggesting prostaglandins may also mediate PTH induced 
vasodilatation (273). It is believed that the vascular and hypercalcaemic 
actions of PTH are separate and arise from different parts of the molecule 
(272).
PTH therefore has the potential to modify cardiovascular responses 
and cardiac composition, yet evidence of its effects in human chronic 
renal disease is conflicting. London compared the echocardiographic 
findings in haemodialysis patients with and without secondary 
hyperparathyroidism, as judged by the degree of bone resorption on 
biopsy, and also looked at healthy controls (274). He found that 
haemodialysis patients with normal bone resorption had both an 
increased left ventricular volume and mass compared to controls, but 
equivalent mass-to-volume ratios. In contrast, patients with bone biopsy 
evidence of hyperparathyroidism had only left ventricular dilatation and 
hence lower mass-to-volume ratios. These patients also had higher heart 
rates and echocardiographic features to suggest augmented contractility, 
which led the authors to suggest that parathyroid hormone might have 
myocardial effects and prevent the development of "adequate" ventricular 
hypertrophy. Jahn, too, observed increased myocardial contractility In 
patients with renal impairment and hyperparathyroidism, particularly after 
volume loading, and through a contrived series of calculations correlated 
responsiveness of the myocardium to increased load with the ratio of 
extracellular ionized calcium to extracellular potassium (239). Although 
these results seem to contradict much of the animal work and Rostands
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view that hyperparathyroidism in humans is associated with depressed 
cardiac function (262), a crucial difference is that myocardial calcium 
content in the better performing hearts was not measured. Perhaps it is 
myocardial calcium rather than PTH that has the negative inotropic effect.
Further indirect evidence for the unfavourable effect of 
hyperparathyroidism, was presented by Lai, who found that cardiac 
performance in haemodialysis patients improved with long-term 
administration of cimetidine (275). He attributed this to suppression of 
uraemic hyperparathyroidism by the H2 antagonist, although could not 
discount a direct cardiac or vasodilatory action. Drüeke, who noted an 
increase in contractility and cardiac ouput in haemodialysis patients 
within two weeks of parathyroidectomy, also concluded that excess 
parathyroid hormone was harmful to the myocardium (276). Such findings 
were not reproduced in smaller studies of haemodialysis subjects before 
and after parathyroidectomy (277, 278). However by employing three 
different methods to achieve a reduction in PTH, namely 
parathyroidectomy, treatment with 1 ,a-hydroxycholecalciferol, or 
manipulation of serum magnesium, McGonigle was able to demonstrate 
some small improvement In echocardiographic cardiac function with each 
manoeuvre (279). It was not clear to what extent the changes could be 
ascribed to alterations in calcium or magnesium concentrations or the 
effects of the vitamin D analogue rather than PTH. 25-hydroxy-vitamin D3 
treatment in haemodialysis patients is associated with a fall in PTH levels 
and an improvement in left ventricular function (280). However it could be 
argued that relative vitamin D deficiency which is known to cause 
hypotonia of skeletal muscle, is also responsilble for myocardial 
dysfunction, and that PTH concentration is irrelevant
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3.3.5 Other factors
It has been suggested that chronic acidosis may compromise 
ventricular function possibly through a reduction in coronary blood flow 
(281). Although the cardiac effects of longstanding acidosis in renal 
failure are unknown, short term studies of acid-base changes induced by 
dialysate buffers show no significant findings (4.4).
However, administration of ascorbic acid may predispose to oxalic 
acid synthesis, and widespread deposition of calcium oxalate. A case of 
myocardial calcinosis complicating hyperoxalaemia in a dialysis patient 
who died of cardiac failure has been reported (282).
Vitamin deficiency is a more common problem among patients with 
renal failure, and Gotlieb, describing a patient with beri-beri, proposed 
thiamine should be measured in all dialysis patients with heart failure but 
no signs of fluid overload (283).
Patients receiving renal replacement therapy might also be at risk 
of developing cardiomyopathies secondary to selenium defiency (284) 
and hypokalaemia (285).
The 21-amino acid polypeptide, endothelin, is a potent 
vasoconstictor with the potential to influence both systemic and renal 
haemodynamics. It has been implicated in the pathogenesis of 
experimental acute renal failure (286), and elevated levels have also 
been described in chronic renal failure (287). Endothelin values are even 
higher in hypertensive haemodialysis patients (288), a group at risk of 
developing severe left ventricular hypertrophy. However, further study is 
necessary to determine whether endothelin plays a role in the 
pathogenesis of cardiac hypertrophy in end-stage renal disease.
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Chapter 4
THE INFLUENCE OF TREATMENT FOR CHRONIC RENAL FAILURE ON THE LEFT VENTRICLE
As well as the effects of uraemia, hypertension, and 
hyperparathyroidism, the heart may also be subjected to additional 
stresses in the form of renal replacement and other therapy.
Section 1
Effects of Arteriovenous Fistulae on the Left Ventricle
It is widely recognised that patients with arteriovenous shunts have 
increased cardiac outputs, stroke volumes and end-diastolic pressures. 
Renal failure patients who already may have hyperdynamic circulations 
because of fluid overload or anaemia are similarly affected, and several 
studies of the change in cardiac output induced by occlusion of 
arteriovenous shunts or fistulae in haemodialysis patients have shown 
significant reductions (289, 290, 291, 292). Neither the type of shunt, nor 
its age appear to influence the degree of elevation of cardiac output (290, 
291) and congestive cardiac failure can develop (289). The assessment 
of the size of the shunt or fistula, in which blood flows may exceed one 
litre per minute (291, 292), will not reliably identify patients at risk of 
cardiac failure, perhaps because these people often have additional 
problems such as impaired left ventricular function or septal hypertrophy 
(291). However, selected patients can benefit from permanent fistula 
closure (289).
The principle mechanism which brings about a fall in cardiac output 
on temporary occlusion of fistulae is a reduction in heart rate (291) which
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has found application as a clinical test of excessive shunting, known as 
the Nicaladoni-Branham sign.
In laboratory experiments in rats without renal failure, shunting 
through either femoral or aortocaval fistulae produces myocardial cell 
enlargement, principally elongation and hence eccentric cardiac 
hypertrophy (293).
Section 2
Haemodialysis and the Left Ventricle
Much has been written about the effects of haemodialysis upon the 
left ventricle. Various techniques ranging from echocardiography to 
radionuclide ventriculography have been applied and varying conclusions 
reached.
4.2.1 Ventricular structure and systolic function
Assessing any impact of haemodialysis on the myocardium is 
difficult because so many other aspects of the uraemic state (chapter 3) 
exert effects. Although hypertrophy is often marked at the outset of 
treatment (294) (figure 4), long term studies of haemodialysis patients 
have shown left ventricular muscle thickness, particularly interventricular 
septal width, increases in size with duration of dialysis dependence (295,
202). The left atrial diameter also progressively enlarges, suggesting the 
development of diastolic dysfunction (202). Only age has been identified 
as a specific risk factor predisposing to left ventricular hypertrophy among 
haemodialysis patients, although blood pressure tends to be higher when 
left ventricular hypertrophy is present (203, 188). The length of each 
dialysis session seems not to influence the morphology of the left
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Figure 4
Post-mortem section of the heart of a 70 year old 
man with renovascular disease who died suddenly, 
shortly after commencing haemodialysis. Marked left 
and moderate right ventricular hypertrophy are evident
ventricle (2 0 2 ), but dialysis itself may lead to an imbalance between 
myocardial oxygen supply and demand and result in myocardial 
underperfusion (296).
A common approach has been to examine the systolic function of 
the left ventricle before and after haemodialysis, and assume any change 
is the direct consequence of the dialysis procedure and removal of 
cardiodepressant uraemic toxins. In this way, several authors have 
concluded that haemodialysis has the beneficial action of improving 
myocardial contractility (297, 189, 194, 192, 218, 222, 296). The 
measurements from which such conclusions were drawn include the 
echocardiographic indices, ejection fraction, fractional shortening and 
velocity of circumferential fibre shortening (Vcf). All are derived from the 
measurement of end-diastolic and end-systolic diameters and for Vcf, left 
ventricular ejection time.
Dialysis which includes ultrafiltration or produces vasodilatation will 
lead to a reduction in circulating blood volume and preload and hence 
smaller ventricular dimensions. Changes in loading conditions therefore 
may be erroneously interpreted as improved contractility, although a 
genuine inotropic effect cannot be discounted. Similarly, studies which 
have attempted to draw distinctions in the response to dialysis between 
patients with and without cardiac failure can also be criticised because of 
deviations from dry weight (196, 194). Not all investigators have 
misinterpreted such changes. Others have recognised that load-induced 
changes in left ventricular end-diastolic pressure may invalidate these 
echocardiographic indices and spuriously point to enhanced contractility 
with haemodialysis (185, 196, 219, 217, 197, 298). Vancheri has even 
used the changes in echocardiographic left ventricular diameters in 
conjunction with phonocardiography to determine the effects of volume 
reduction through haemodialysis on diastolic time intervals and hence left
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ventricular filling time (299). Not only did this study highlight the influence 
of loading conditions on left ventricular size, but it demonstrated a 
prolongation of the isovolaemic relaxation time with dialysis for any given 
R-R interval, thus implying less good diastolic function.
The difficulties of assessing left ventricular systolic function by 
means of echocardiography were reviewed by Tomson (300) and have 
been addressed in studies of isolated ultrafiltration without dialysis and of 
isovolaemic dialysis. In order to dissociate the effects of changes in filling 
pressure from removal of uraemic toxins, Nixon et al undertook serial 
echocardiography across haemodialysis with and without weight loss and 
ultrafiltration (301). They confirmed that fluid loss through ultrafiltration 
alone caused a reduction in end-diastolic volume and stroke volume, 
without affecting end-systolic volume or Vcf, a true Frank-Starling 
response. Following haemodialysis, without manipulation of volume, 
biochemical improvements were accompanied by a decrease in end- 
systolic volume and increases in stroke volume, ejection fraction, and 
Vcf, all signifying a genuine rise in contractility. The same group also 
examined the effects of different types of dialysate on cardiac function.
4.2.2 Dialysate and ventricular function
If haemodialysis is associated with an improvement in cardiac 
contractility, is this because of removal of a dialysable uraemic toxin or 
addition of an inotropic agent? In order to correct metabolic acidosis of 
renal failure during haemodialysis it is necessary to include a buffer in the 
dialysate. Sodium acetate which in vivo is metabolised to bicarbonate 
was the first to be employed, but causes a marked rise in serum acetate 
levels in approximately twenty-five percent of patients who are slow 
metabolisers (302). As acetate has a vasodilatory action and produces a
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tachycardia, it may predispose to intradialytic hypotension (303,302), 
although evidence supporting a specific cardiodepressant action is 
conflicting (304).
When developments in dialysate production permitted bicarbonate 
to be used as an alternative buffer, this was claimed to be superior agent, 
less likely to cause nausea, tachycardia, relative hypoxaemia, or left 
ventricular dysfunction (305, 303, 220, 306). Patients with impaired left 
ventricular function were said to experience a greater increase in 
contractility with bicarbonate dialysis than with acetate, although once 
more the influence of preload on echocardiographic indices of systolic 
function was in disregarded (307). Anderson and Mehta who investigated 
isovolaemic dialyses, in albeit small numbers of stable patients, 
overcame this problem and contradicted reports of acetate's 
cardiodepressant properties (308, 309). They found that both dialysis 
buffers caused comparable increases in left ventricular contractility, at 
least in their small groups of patients without heart failure (308,309). 
Krishna on the other hand, who used the ratio of end-systolic pressure to 
end-systolic volume as a load independent index of myocardial 
contractility in eight patients, found no significant change in systolic 
function with either acetate or bicarbonate, though there was a tendency 
for the ratio to fall and inclusion of more patients might have altered the 
conclusion (221). In clinical practice bicarbonate is the preferred buffer, 
particularly if patients have a history of cardiac disease or instablilty 
during haemodialysis.
The underlying mechanism for any inotropic effect is not yet clear, 
although Nixon's group in another pioneering study of isovolaemic 
dialysis, found that changes in cardiac function were most closely related 
to an increase in plasma ionised calcium (310). Neither the incomplete 
removal of uraemic toxins, nor a rise in serum bicarbonate concentrations
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achieved the same degree of improvement, but noradrenaline levels were 
higher both before and after calcium manipulation, an Important factor 
about which the authors made no comment (310). Nevertheless, others 
have observed an improvement in myocardial performance after 
correction of low extracellular ionised calcium levels (311, 312), 
suggesting the effect is indeed genuine.
The significance of changing prostaglandin concentrations during 
dialysis is unclear (313), but might predispose to haemodynamic 
instability.
4.2.3 Haemodialysis and arrhythmias
Another factor which favours dialysis hypotension is the 
disturbance of cardiac rhythm. Not only are ventricular arrhythmias more 
common among patients with end-stage renal disease (Chapter 3.2.1), 
but they frequently occur during and up to ten hours after the dialysis 
procedure itself (211, 314, 213). Use of low potassium dialysate may 
exacerbate the problem (314), while reduction in oxygen delivery could 
also contribute (296), especially as hypertrophied ventricles appear more 
susceptible (212). In addition, the incidence of first degree heart block 
may increase with the number of years of dialysis treatment (212). The 
influence of low serum calcium on arrhythmias is uncertain, but the 
temporal relationship with dialysis would argue against an association.
Section 3
Peritoneal Dialysis and the Left Ventricle
There are fewer studies of the heart in patients receiving the newer 
type of dialysis, continuous ambulatory peritoneal dialysis (CARD), and
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the results are conflicting. Leenan suggested that because hypertension 
is often better controlled with CARD, left ventricular mass should fall 
(316). With a cube formula, he was able to demonstrate a reduction in 
mass, attributable to a reduction in left ventricular wall thickness and 
more importantly to a decrease in end-diastolic dimension in fourteen of 
fifteen hypertensive CARD subjects. He did not explore the impact of this 
internal cavity change on the derived left ventricular mass or systolic 
function (315) . He also failed to relate left ventricular mass to patient
weight, which frequently increases with CARD treatment because of the 
absorption of glucose from intraperitoneal dialysate. Nor did he discuss 
the degree of anaemia in his patients. Similar reversal of hypertrophy was 
reported by Deligiannis, who followed ten CARD patients for a mean of 
twenty-two months during which time the mean haemoglobin rose (295)
In contrast, Eisenberg who did take account of weight, and used 
similar methods to determine left ventricular mass, found that there was a 
tendency for hypertrophy to increase with ongoing dialysis (316). It is 
perhaps relevant that blood pressure and haemoglobin remained 
unchanged after the introduction of CARD and only systolic blood 
pressure correlated significantly with the degree of left ventricular 
hypertrophy. Ratients with severe hypertrophy had a high mortality.
More recently HCiting et al concluded that left ventricular 
hypertrophy in CARD patients was not the result of hypertension, but 
related to hyperdynamic circulations and inefficient dialysis (317). The 
latter conclusion is unsubstantiated and large studies comparing the 
cardiac consequences of CARD and haemodialysis are lacking.
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Section 4
Renal Transplantation and the Left Ventricle
One of the earliest studies of cardiac function in patients with renal 
transplants proved to be most useful in that it demonstrated that 
haemodynamic measurements in transplant recipients were no different 
from those of healthy controls (233). Cardiac indices after transplantation, 
despite a slightly lower mean haematocrit, were normal. Furthermore, a 
comparison of hypertensive and normotensive transplanted patients 
revealed similar blood volumes, plasma renin concentrations and renal 
function, thereby indicating that increased peripheral vascular resistance 
must be responsible for raised blood pressure (233). However the precise 
cause was not clear. Correction of anaemia was assumed to be the main 
factor in leading to resolution of the high output state characteristic of 
end-stage renal failure.
Since then a number of other findings have been described. The 
prevalence of left ventricular hypertrophy in patients with renal allografts, 
as assessed by a variety of echocardiographic measures, is consistently 
reported at around forty percent, lower than in dialysis populations 
(203,318). Despite this, electrocardiographic appearances may remain 
unchanged (319). With only one exception (320), serial studies of left 
ventricular morphology across renal transplantation have agreed, by 
which ever echocardiographic criteria were employed, that left ventricular 
mass falls significantly (321, 322, 295, 323, 324). This occurs early, 
within the first three to six months (323, 324), and although it coincides 
with a return to a euvolaemic state, there has been a tendency for 
investigators to neglect the significance of concurrent events or their 
influence upon echocardiographic indices.
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Instead authors have sought risk factors for hypertrophy after 
transplantation and identified only the number of antihypertensive agents 
required and therefore by implication, raised blood pressure (323, 318,
203). Hypertension is more common than might be anticipated after 
restoration of renal function. As many as sixty-five percent of patients 
may require antihypertensive treatment in the post-transplant period 
because of steroid and cyclosporin treatment, diseased renin-secreting 
native kidneys, ongoing renal impairment (perhaps as a consequence of 
chronic rejection), and development of stenosis in the transplant renal 
artery (325).
Many studies have also described improved systolic ventricular 
function following renal transplantation (320, 319, 295, 324), which would 
accord with the lower incidence of cardiac failure in transplant patients 
(6 ). Case-reports have even cited partial or complete resolution of 
intractable cardiac failure after transplant surgery and attributed this to 
the elimination of uraemic toxins, although the authors cannot discount 
the possibilty that the cardiac failure was due to fluid overload (326). 
Ikaheimo has suggested that the response of cardiac function to renal 
transplantation can be predicted by the improvement which results from 
weight removal through haemodialysis (321). Similarly the transplant 
mediated alleviation of the adverse effects of anaemia and 
hyperparathyroidism have often been disregarded.
In contrast, diastolic ventricular function may remain impaired after 
successful renal transplantation and continue to pose the risk of 
pulmonary oedema, in spite of regression of left ventricular hypertrophy 
(324).
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Section 5
Drugs and the Left Ventricle
The actions of many drugs which influence the morphology or 
function of the left ventricle, might plausibly be potentiated if drug 
elimination is delayed as a result of renal failure. In practice, the evidence 
for this is limited, and with appropriate dosing, the cardiac effects of drugs 
should be assumed to be unchanged. These include regression of left 
ventricular hypertrophy in hypertension with methyl dopa, clonidine, R- 
adrenergic receptor blocking agents, angiotensin converting enzyme 
inhibitors and certain calcium channel blocking drugs (327, 328). Such 
reversal may occur independently of a blood pressure lowering effect 
(327). Vasodilator treatment on the other hand can lead to an increase in 
cardiac mass (327).
However several drugs deserve attention because of their 
widespread use in patients receiving renal replacement therapy.
4.5.1 Beneficial therapy
As well as causing regression of ventricular hypertrophy, it has 
been suggested that calcium channel blockade with verapamil may 
reduce the incidence of dialysis related hypotension in patients with left 
ventricular hypertrophy and presumed diastolic dysfunction (329).
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4.6.2 Adverse therapy
It is of concern that a number of agents may have the potential to 
increase cardiac mass in patients with end-stage renal failure.
Aluminium loading through use of aluminium containing phosphate 
binders, has been associated with cardiac hypertrophy in haemodialysed 
patients (330) and this in turn might be related to intradialyctic 
hypotension or even sudden cardiac death (331).
Repeated blood transfusion in anaemic uraemic patients also 
poses the theoretical risk of haemosiderosis involving the myocardium, 
though evidence to support this view is lacking.
Cyclosporin constitutes a greater risk: as well as having adverse 
vascular side-effects, this first-line immunosuppressive agent may cause 
hypertension and left ventricular hypertrophy, at least in cardiac 
transplant recipients (332). As most of the studies demonstrating 
regression of cardiac hypertrophy after renal transplantation were 
undertaken in the pre-cyclosporin era, the importance of this action is not 
known.
Another drug with hypertension as a side-effect is erythropoietin. 
One of the questions, this thesis will address is whether the beneficial 
effects on the heart of treating anaemia with erythropoietin outweigh the 
risks of increased blood pressure and viscosity.
Beta adrenergic blocking agents may impede the expected 
improvement in systolic function associated with haemodialysis in 
patients with increased muscle mass (333).
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Chapter 5
AIMS AND METHODS 
Section 1
Aims of this thesis
The main aim of this thesis was to investigate prospectively the 
prevalence of left ventricular hypertrophy in patients with end-stage renal 
failure selected for renal transplantation and to assess the influence of 
transplantation on left ventricular morphology and function using 
approved echocardiographic and Doppler techniques. In addition the 
influence of left ventricular mass on the outcome of patients presenting 
for renal transplantation was studied.
As renal transplantation not only corrects uraemia, but also 
commonly leads to the reversal of anaemia and hyperparathroidism, 
some of the first patients to be treated with the new drug recombinant 
human erythropoietin and patients scheduled for subtotal 
parathyroidectomy served as control groups.
5.1.1 Study subjects - rationale
The principle group studied comprised a consecutive series of 
adults about to undergo renal transplantation at the Western Infirmary 
renal unit in Glasgow between January 1988 and July 1990. As 
echocardiography was performed by the author alone and only with 
informed consent of the patients according to the local ethical commitee's 
guidelines, the series was unavoidably incomplete. One hundred and fifty 
three (67%) of a possible 228 pre-transplant echoes were obtained.
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During the course of this study, the unit became involved in a 
double-blinded, placebo controlled trial of the value of the prostaglandin 
analogue Misoprostol in preventing early renal allograft dysfunction. The 
author was responsible for patient recruitment and supervision. Although 
this drug has no known cardiac effects, prostaglandin analogues can 
cause peripheral vasodilatation and could therefore potentially affect 
blood pressure and left ventricular mass. Hence a comparison of treated 
and untreated patients was made.
Some unexpected findings in the course of the study led to 
questions about the influence of volume overload on echocardiograhic 
indices, so in order to determine whether reduction in circulating volume 
affects measurement of left ventricular mass in patients with end-stage 
renal failure, echocardiography was performed before and after 
haemodialysis with ultrafiltration.
5.1.2 Presentation
The findings of these separate studies will be presented and 
discussed as follows:
Chapter 6  The left ventricle in a dialysis population
Chapter 7 Renal transplantation and the left ventricle
Chapter 8 Anaemia and the left ventricle
Chapter 9 Hyperparathyroidism and the left ventricle
Chapter 10 Discussion
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Section2
Methods
As the techniques applied to the various study populations are 
similar, they will be described only once.
5.2.1 Patients
All patients were seen by the author, who explained the nature of 
the study, sought permission according to the local ethical committee's 
guidelines, and obtained a full medical history. She undertook general 
and cardiovascular examinations, obtained blood for biochemical, 
haematological and in some cases, rheological measurements, and then 
performed echocardiographic and Doppler examinations.
5.2.2 Blood pressure
Blood pressure was measured on the day of echocardiography using a 
standard mercury sphygmomanometer after five minutes with the patient 
in a seated position. Routine drug treatment was not discontinued 
beforehand because of the unpredictabilty of the timing of cadaveric renal 
transplantaion and the importance of good blood pressure control in more 
elective live donor transplanatation. As blood pressure measurement 
immediately before surgery may not be representative, the average of 
this and the two most recent clinic or pre-dialysis blood pressure 
recordings was calculated. Mean blood pressure on the day of 
echocardiography was also determined according to the formula:-
Mean pressure = diastolic pressure + pulse pressure/3
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5.2.3 Body Surface Area
Patients heights (cm) were recorded and their weights (kg) 
measured without outdoor clothing or shoes. Body surface area (bsa) was 
determined according to Boyd's formula and expressed in m2;
bsa = 3.2 * htO-3* wt[0-7285-0.0188*log10 (wt)]/io4 m2
where ht = height in centimetres 
wt = weight in grams 
* = multiplied by
5.2.4 Biochemical measurements
Urea, electrolytes, calcium, total protein, albumin, phosphate, and 
alkaline phosphatase were all measured on a SMAC-I (Technical 
Instruments Corporation, Basingstoke, UK). The total serum calcium 
values were corrected for albumin concentration using the formula:
Galciumc = calciumm+ 0.02 (40 - albuminm) 
where Galciumc = corrected calcium
Galciumm = measured calcium 
Albuminm = measured albumin
Serum parathyroid hormone was measured with a two site 
immunometric assay for intact (1-84) parathyroid hormone using
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monoclonal antibodies. All laboratory normal ranges are give in Appendix 
1.
6.2.4 Haematological measurements
Haemoglobin was measured with an automated Coulter counter 
(Coulter S Plus IV 3D).
5.2.6 Rheological measurements
Whole blood viscosity and plasma viscosity were measured by Ms 
Karen McLaughlin of Department of Medicine, Glasgow Royal Infirmary 
on a rotational viscometer, within 6  hours of the blood sample being 
withdrawn into an EDTA tube. The measurements were made at a 
temperature of 25°C and at high shear rates of 200s-^. The SI unit of 
viscosity is the milli-pascal-second (mPa.s)
The corrected viscosity represented the viscosity corrected to a 
standard haematocrit of 0.45 (BBC microcomputer and programme), 
while the relative viscosity was calculated from the ratio corrected 
viscosity/plasma viscosity.
5.2.6 Echocardiographic and Doppler
Examinations
M-mode and two dimensional (2-D) echocardiography and Doppler 
assessments were all undertaken by the author using a Hewlett-Packard 
ultrasound unit (model 77020A) with a 2.5 MHz transducer. Patients were 
studied in the left decubitus position with the transducer in the third to the 
fifth intercostal space. 2-D echocardiography permitted simultaneous
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visualisation of the left ventricular cavity and hence accurate positioning 
of the M-mode cursor. Both 2-D and M-mode scans were recorded on 
video and an M-mode record was also taken on six inch light-sensitive 
paper with a paper speed of 50mm/second. These paper records were 
then coded so that the identity of the patient and the timing of the scan 
was unknown to the author when later analysing the traces.
Only echocardiographic frames with clear images and continuous 
lines were deemed suitable for analysis, which was performed using a 
digitising tablet (Kontron Ltd) and a microcomputer (Cardio 80). These 
instruments report dimensions to two decimal points, but for the purpose 
of tabular representation of wall thicknesses only one decimal point was 
quoted. The measurements are discussed in 5.3.1.
As is frequently reported in echocardiographic research, it is often 
possible to obtain satisfactory recordings in one "view", but not another in 
the same individual. Hence a complete data-set was not always obtained 
for every patient.
Mitral flow was sampled using a 2.5 MHz transducer modified to 
deliver and receive doppler signals, and was recorded on light-sensitive 
paper. The peak velocities from early "passive" ventricular filling (the E 
wave) and later "active" ventricular filling from atrial contraction (the A 
wave) were measured with a ruler by the author on recordings coded for 
anonymity (figure 5) (165).
With the exception of pre-transplant and post-dialysis 
assessments, all echocardiography in haemodialysis patients was 
undertaken immediately before a haemodialysis session.
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E wave A wave
Figure 5
Doppler recording of transmitral flow, the E wave is the early 
velocity peak due to passive ventricular filling and the A wave is 
due to atrial contraction
Section 3
Echocardiographic measurements
5.3.1 Left ventricular dimensions
The interventricular septal thickness (IVST), the left ventricular 
internal dimension (LVID) and posterior wall thickness (PWT) were all 
measured just distal to the tips of the mitral valve leaflets at the end of 
diastole, represented by the peak of the 'R' wave on a simultaneous BCG 
recording (Figure 6 ). IVST included the endocardial layers on either side 
of the interventricular septum, while the endocardial, but not the 
pericardial surface of the posterior left ventricular wall was regarded as 
contributing to PWT. Measurements of IVST, LVID and PWT were made 
over three consecutive cardiac cycles and the mean values calculated.
Left ventricular wall thickness at post mortem has been shown to 
be similar to echocardiographic PWT and IVST in systole but greater than 
wall thickness in diastole (334), perhaps because hearts at necropsy are 
in the systolic phase of the cardiac cycle, while echocardiographic 
measurements are made during diastole. As left ventricular mass 
determinations are not subject to such discrepancies, hypertrophy may 
thus be better assessed.
The mean echocardiographic wall thickness (MWT) was also 
determined according to the formula:-
MWT = (IVST + PWT)/2
Relative wall thickness (RWT) was calculated thus:- 
RWT = 2PWT/LVID
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Figure 6
Diagram of the left ventricular dimensions measured 
by M-mode echocardiography
5.3.2 Left atrial diameter
The maximum diameter of the left atrium at the end of ventricular 
systole was measured, as recommended by the American Society of 
Echocardiography (335) (figure 7). This may be valuable as indirect 
evidence of left ventricular diastolic dysfunction (336).
5.3.3 Left ventricular mass
Apart from consideration of wall thickness, a number of methods of 
calculating left ventricular mass have been described. However, only 
Devereux and Relchek's method (51) has been anatomically validated by 
post-mortem measurement of left ventricular weight and therefore their M- 
mode modified cube formula was chosen as the preferred method in this 
study.
It comprises a cube formula which incorporates the Penn 
convention of excluding endocardial widths from the measurements of the 
interventricular septum and posterior wall and including endocardial 
thickness in the measurement of the LVID (Figure 8 ). The derived volume 
of the left ventricular cavity is subtracted from the total derived left 
ventricular volume, and corrected for the specific gravity of muscle, as 
follows.
LVM (g) = 1.04([LVIDp+PWTp+IVSTp]3-[LVIDp]3) - 13.6
where 1.04 = density of myocardium
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left atrial diameter
Figure 7
M-mode echocardiographic assessment of left atrial 
diameter
■iSE
suindord
Penn
{itnveniion
Figure 8
Penn convention measurements used to determine left 
ventricular mass according to the method of 
Devereux and Reichek
LVIDp = left ventricular diastolic internaldiameter according to Penn
PWTp = left ventricular diastolic posteriorwall thickness according to Penn
IVSTp = thickness of the interventriclar septumin diastole according to Penn
These measurements were made over three consecutive cardiac 
cycles and the mean values calculated. Left ventricular mass was related 
to body surface area and expressed as the left ventricular mass index 
(90).
Devereux and Reichek's original validation was undertaken in 34 
terminally ill patients with a variety of problems, the majority of whom had 
left ventricular cavities of normal dimensions (51). Four were reported to 
have renal failure, and analyses of clinical subgroups still showed the 
method to be accurate (for further discussion see page 81).
The value of two electrocardiographic methods for the diagnosis of 
left ventricular hypertrophy was assessed in a dialysis population. Gubner 
and Ungerleider, through a comparison of hypertensive and non­
hypertensive patients' electrocardiographs in 1942, considered LVH to be 
present if the sum of the R wave in lead I and the S wave in lead III 
exceeded 25mm (337). In 1949 Sokolov and Lyon defined a set of criteria 
using which distinguished patients with hypertension, aortic valve disease 
or coarctation of the aorta and presumed LVH from normal subjects 
(338). These were later subjected to a post-mortem validation by 
Allenstein and Mori when it was found that the QRS voltage changes 
amongst the criteria they originally described were the most sensitive and 
reliable indicators of the presence of LVH (339). These comprised the 
sum of the R wave in V5 and the S wave in lead VI exceeding 35mm.
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6.3.4 Left ventricular volume
In view of a predisposition of dialysis patients (most of whom are 
anuric or oliguric) to volume overload, particularly in the period 
immediately preceeding dialysis, left ventricular volume was assessed at 
both end-diastole and end-systole according to the method described by 
Tortoledo (340). The technique has been shown to correlate well with 
biplane angiographic measurements and involves measuring two 
diameters in the parasternal long axis view (figure 9) and three diameters 
and a long axis in an apical four chamber view (figure 10) at end-diastole. 
The measurements are repeated at end-systole (figure 11) and from a 
derived formula, previously validated by Tortoledo et al (340) which 
determines ejection fraction and hence stroke volume (SV=end-diastolic 
volume (EDV) x ejection fraction), the end-systolic volume (ESV) can be 
derived (ESV=EDV-SV).
5.3.5 Normal ranges
Normal ranges for echocardiographic measurements have been 
defined through the study of large populations of people of differing ages 
with good health and normal blood pressure (341). To repeat such large 
studies would be an unecessary and time consuming task and therefore 
predetermined normal ranges have been accepted (Appendix 3).
5.3.6 Reproducibility of echocardiographic measurements
The reproducibiity of echocardiographic left ventricular 
measurements in a single subject was calculated by measuring left
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Figure 9
Left parasternal long axis view of left ventricle for 
determining end-diastolic volume - Tortoledo method
Figure 10
Apical four chamber view of left ventricle in diastole for 
determining end-diastolic volume - Tortoledo method
Figure 11
Apical four chamber view in systole for determining 
end-systolic volume - Tortoledo method
ventricular dimensions and volume in a healthy 21 year old volunteer on 
ten different occasions over ten days. The coefficient of variation was 
found to be 4.9% with respect to mass (51) and 4.3% with respect to end- 
diastolic volume (340). The author also repeated left ventricular 
measurements on the same M-mode echocardiogram on ten different 
occasions with an acceptable intra-observer coefficient of variation of 
1.9%. A second echocardiographer with experience of determining left 
ventricular mass, but unaware of the nature of the scans, repeated 
measuremnts in eleven pre- and post-treatment echocardiograms, 
achieving a correlation of 0.98.
Section 4 Patients
Details of the patients who participated in the studies are given in 
appendix 4
Section 6 Statistical analyses
For comparison of paired data the students paired f test was used 
for normally distributed data and the paired Wilcoxon test for non- 
parametric data. For non-paired data which were not normally distributed, 
the Mann-Whitney test was applied. All results are given as 95% 
confidence intervals (95%CI) and p values, unless clearly not significant 
(ns).
Conditional logistic regression analyses were performed to look at 
factors which at the outset of renal transplantation might be related to
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ventricular size. The Cox's proportional hazards method was used to 
assess these factors in relation to patient survival.
5.3.3 Left ventricular mass (continued)
Serial M-mode measurements may be flawed if patient or 
transducer position are not accurately reproduced. Two-dimensional 
echocardiography provides a guide to the left ventricle and helps to 
reduce angulation error, but may not improve results of experienced M- 
mode operators (90).
Several investigators have suggested that techniques relying on 
two-dimensional echocardiography alone give superior estimations of left 
ventricular mass (351, 352). These involve tracing the endocardial and 
epicardial surfaces of the left ventricle on stored, preferably diastolic 
images then applying formulae derived from geometric models of the left 
ventricle.
However such planimetric two-dimensional methods are still limited 
by poor image resolution and are inaccurate in cases where ventricular 
anatomy is distorted. Their main advantage is that they take account of 
the Important influence of cavity volume on left ventricular mass 
determination (353).
Three dimensional reconstruction techniques may overcome many 
of these problems in the future (354).
I
I
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Chapter 6
THE LEFT VENTRICLE IN A DIALYSIS POPULATION
In the course of investigating the effects of renal transplantation, 
erythropoietin treatment and parathyroidectomy on the echocardiographic 
appearances of the myocardium, 378 echocardiograms from 223 patients 
receiving regular renal replacement therapy were recorded. However the 
original intention to treat was not fulfilled in 14 cases for a variety of 
reasons such as unsuitable organ for transplantation, positive 
crossmatch, or revision of proposed therapeutic approach. In addition 20 
random examinations of stable haemodialysis and CARD patients were 
performed and together these echoes constituted the "dialysis only" 
group.
In all there were 220 "baseline" echoes from 217 dialysis patients 
(table 2). Despite selection for renal transplantation, erythropoietin 
therapy or sub-total parathyroidectomy, these people formed a 
representative sample of the local dialysis population most of whom were 
potential transplant recipients. A minority of patients would not receive a 
renal allograft on the grounds of advanced age, co-existant disease or a 
high degree of sensitisation.
By performing a cross-sectional comparison, the influence on the 
left ventricular echocardiographic appearances of sex, age, renal 
disease, hypertension, ischaemic heart disease, smoking habit and 
dialysis type and duration was examined.
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TYPE OF ECHO NUMBER (* %)
Pre-transplant 153 (19 1 2 )
Pre-erythropoietin 20 (1 5)
Pre-parathyroidectomy 10 (2 2 0 )
Dialysis only 34 (2 6 )
TOTAL 217 (24 1 1 )
Table 2 Baseline echoes in dialysis patients
(* - % echoes of insufflent clarity to fully analyse)
Section 1
Sex, age, and the left ventricle
Of the 217 dialysis patients, 128 were male and 89 were female. 
Their mean ages were comparable (table 3) as were their blood 
pressures. However more of the men had a history of hypertension and 
as a group were taking significantly more antihypertensive medications 
than the women. As might be expected fewer women had a past history 
of cardiac disease and women had slightly lower haemoglobin 
concentrations.
The left ventricles in men were larger than in women (table 4). The 
interventricular septal thickness and end-diastolic dimension were 
significantly greater and consequently the derived left ventricular mass 
was also
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MALE FEMALE
NUMBER 128 89
mean AGE (range) 39.8 (18-69) 41.9(15-68)
BSA m2 (mean±SD) 1.81±0.21 1.61 ±0 .2 0
SBP (mean±SD) 147±21 144±22
DBP (mean±SD) 88±13 8 6 ± 1 2
PREV. HT 105 (82%) 64 (72%)
BP drugs(median) 1 0 *
Hb (mean±SD) 9.2±3.7 8.7±1.9
PTH (pmols/l) 38±56 41 ±47
CARDIAC history 31 (24%) 13(15%)
Table 3 Characteristics of male and female dialysis patients
* (0.002- 1.001) p=0.0013
median * MALE FEMALE 95%C1 p
IVSTcm 27 1.6 1.5 (0.02-0.30) p=0.014
PWTcm 27 1.0 0.9 (0.00-0.16) p=0.09
EDDcm 27 5.5 4.7 (0.41 - 0.93) p<0.001
LVMIg/m2 27 172 127 (21.4-56.9) p<0.001
EDVml 67 152 105 (28 - 55) p<0.001
Table 4 Left ventricular dimensions of male and female dialysis patients* - number of missing values - applies in later whole group analyses unless stated otherwise
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greater. However, even allowing for the increased body surface areas of 
the men (as reflected by the left ventricular mass indices), there was still 
a significant difference between male and female left ventricular mass. 
The end-diastolic volumes of the men also appeared disproportionately 
increased.
6.1.2 Age
Left ventricular measurements of the 217 dialysis subjects were 
examined and found to have a tendency to increase with age (table 5).
AGE <20 20-29 30-39 40-49 50-59 60-69
Number 12 49 45 49 44 18
Male % 50 61 71 53 59 44
HT% 35 71 84 84 80 8
IVSTcm 1.4 1.5 1.6 1.5 1.7 1.6
PWTcm 0.9 1.0 1.1 1 .0 1 .0 1.1
EDDcm 4.8 5.2 5.0 5.3 5.3 5.2
LVMlg/m2 117 141 169 155 176 175
EDVml 151 123 137 126 136 131
Table 5 LV dimensions and details of sex and hypertension according to age
There was also a trend for the prevalence of hypertension requiring 
medical therapy to increase with age, but the proportion of males (who 
might have been expected to have larger ventricles) was lower in the 
older age groups.
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Section 2
Renal disease and the left ventricle
The causes of renal failure in the 217 dialysis patients were 
representative of the commonly reported causes of EBRD (3); 
glomerulonephritis was the most frequent underlying pathology in 31%, 
9% patients had type I diabetes mellitus and in 6.5% patients who 
presented late with small kidneys, the cause was unclear. There was a 
slight excess (2 2 %) of patients with reflux nephropathy or pyelonephritis. 
Left ventricular size varied, according to the primary renal disease (table 
6 ). The lowest median left ventricular mass index was seen in the group 
with ESRF of uncertain cause and the fewest hypertensive patients, while 
the highest median LVM I was in patients with renovascular disease, all 
but one of whom had been treated for hypertension.
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Renal
disease
No.pts
(%HT)
LVMI
g/m2
IVST
cm
PWT
cm
EDD
cm
EDV
ml
Unknown 14(57) 141 1.6 1.0 4.7 136
APKD 19(89) 145 1.7 0.9 4.5 108
Reflux / PN 48 (6 6 ) 147 1.5 1.0 5.2 125
GN 68  (82) 150 1.6 1.0 5.4 144
DM type 1 19(84) 153 1.6 1.1 4.9 115
RV 14(92) 2 1 0 2 .0 1.0 5.1 112
Table 6  LV dimensions and renal disease - median values given
(APKD - adult polycystic kidney disease,PN - pyelonephritis, GN- glomerulonephritis, DM - diabetes mellitus, RV - renovascular %HT - percentage of patients with history of hypertension)
6.2.2 Hypertension
The variation of LVMI with type of renal disease suggested 
hypertension might be responsible. A comparison of LV dimensions of 
patients with a history of hypertension requiring treatment,patients with 
previous malignant phase hypertension (grade 3 or 4 retinal changes), or 
those with no need for antihypertensive medication (table 7), confirmed 
an association not only between hypertension and increased LV mass but 
also between severe hypertension and marked left ventricular 
hypertrophy.
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Pt
No
LVMI
g/m2
IVST
cm
PWT
cm
EDD
cm
EDV
ml
No HT 48 130 1.5 0.9 4.8 122
Hypertension 169 167* 1 .6 1 .0 5.3 136
(Malignant) 12 230 2.1 0.9 4.8 114
Table 7 Median LV dimensions and hypertension (HT)
* Difference between median non-hypertensive and hypertensive LVMI (14.45 - 55.69), p=0.001
6.2.3 Previous myocardiai infarction (Mi)
'i.
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S | i
Pt
No
LVMI
g/m2
IVST
cm
PWT
cm
EDD
cm
EDV
ml
No Ml 207 151 1.6 1 .0 5.2 130
Previous Ml 10 176 1.7 0 .8 5.9* 158$
Table 8 Median LV dimensions and previous Ml 
* 95%CI (0.3 - 1.4), p=0.0037 
$ 95%CI (-73 - -0.0), p=0.057)
Although the median LVMI of the 10 dialysis patients who had 
suffered a previous myocardial infarction was greater than those of 
patients with no history of myocardial infarction (table 8 ), this difference 
was not statistically significant. However the group of Ml patients was 
small and the possibility that LVH predisposed to Ml cannot be 
discounted. Increased susceptability to ischaemic injury through relative 
lack of blood supply is well recognised in other patients with cardiac 
hypertrophy (60,140)
In contrast following Ml patients had a significantly greater end-
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diastolic dimension, and a tendency to have a larger end-diastolic volume 
most likely as a consequence of ventricular damage and dilatation.
6.2.4 Smoking and LV dimensions
Pt
No
LVMI
g/m2
IVST
cm
PWT
cm
EDD
cm
EDV
ml
Non-smokers 115 148 1.6 1.0 5.1 123
Current+exsmokers 102 167 1.6 1.0 5.3 143
Current smokers only 70 172 1.6 1.0 5.3 136
Table 9 LV dimensions and smoking habit
Although both LV mass and LV end-diastolic diameter were slightly 
greater in the smoking compared to the non-smoking groups these 
differences were not significant (table 9).
Section 3 Dialysis and LV dimensions
At the time of the first dialysis echo, 129 patients were receiving 
haemodialysis and 88  patients CAPO. LV size did not vary with the 
method of dialysis employed (table 10 ).
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Pt
No
LVMI
g/m2
IVST
cm
PWT
cm
EDD
cm
EDV
ml
Haemodialysis 88 154 1.6 1 .0 5.2 126
CAPD 129 155 1 .6 1 .0 5.2 135
Table 10 Median LV dimensions of haemodialysis and CAPD patients
6.3.2 Duration of renai replacement therapy (RRT)
Months of 
RRT
Pt
no
LVMI
g/m2
IVST
cm
PWT
cm
EDD
cm
EDV
ml
<3 15 161 1.75 1.07 5.55 201
3-5 10 137 1.51 1.09 4.75 109
6 -1 2 30 135 1.50 1.05 5.20 127
13-24 38 143 1.59 1 .00 5.20 137
25-36 26 125 1.50 0.90 5.30 165
37-60 28 170 1.62 1 .00 5.30 143
61-84 32 167 1.60 0.90 5.40 118
84-120 14 129 1.65 0.93 4.40 106
> 1 2 0 24 182 1.50 1 .20 5.10 120
Table 11 Median LV dimensions and duration of renal replacement therapy
As there were no significant differences between CAPD and 
haemodialysis patients' ventricular size, the two groups were combined to 
perform a cross-sectional study on the effect of duration of dialysis on left
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ventricular size (table 11). In reality many patients change from one mode 
of dialysis to another for medical or personal reasons or experience a 
period with a renal transplant interspersed. Of the 24 patients who had 
been receiving renal replacement tharapy for more than 10 years, only 
four had not been transplanted.
Table 11 data suggest a tendency for interventricular septal wall 
thickness, derived LV mass and end-diastolic volume to decrease within 
the first few months of dialysis. However the patient numbers were small 
and the observations did not reach statistical significance. Similarly the 
increased left ventricular mass index beyond 1 20  months of renal 
replacement therapy applied to a relatively small number of patients, but 
was significantly different from the median LVMI of patients on dialysis 
less than three years (table 12). Only the posterior wall thickness differed 
in the two groups.
Duration of 
RRT
Pt
No
LVMI
g/m2
IVST
cm
PWT
cm
EDD
cm
EDV
ml
<36 months 119 142 1.52 1.00 5.20 138
>120 months 24 182* 1.50 1.20 5.10 120
"missing values 22 22 22 22 39
Table 12 Median LV dimensions of patients on renalreplacement therapy for less than 3 years and more than 10  years.*(-64.4--6.58), p=0.019
Excluding the 65 patients who had previously been transplanted 
resulted in a median LVMI of 159 g/m^ for the remaining dialysis patients 
and did not significantly alter the findings.
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Section 4 Serial echocardiography in dialysis 
patients
Of the 34 patients who had an initial "dialysis only" echo, 27 had a 
follow-up echocardiogram performed and 8 had a third. Seven did not 
have a second echo, because of death in 3 cases and transfer to another 
hospital in 4 cases
The interval between echoes was not constant and ranged from 7 
to 99 weeks, with a mean value of 32 weeks. Two of the patients were 
commencing renal replacement therapy at the time of the first echo.
The characteristics of the dialysis patients with two echoes did not 
change between echoes (table 13). An example M-mode echocardiogram 
from a dialysis patient with marked LVH is shown (figure 12).
Although the median LV dimensions of the dialysis patients did not 
change with time (table 14), there was considerable individual variation in 
LVMI (figure 13), which could not be explained by the type of dialysis or 
the duration of treatment.
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posterior wall interventricular septum
Figure 12
Pre-transplant M-mode echocardiogram showing 
marked thickening of the interventricular septum 
and posterior ventricular wall
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Haemodialysis
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Figure 13
Left ventricular mass indices in patients receiving 
regular dialysis treatment (median values shown)
TIME 1 TIME 2
BSA(mean±SD) 1.66±0.23 1.66±0.23
SBP (mean±SD) 144±20 145±27
DBP (mean±SD) 82±12 86±18
MBP (mean±SD) 101±19 106±19
BP drugs(median) 1.0 0
median Hb (g/dl) 8.1 8 .2
medianPTH (pmols/i) 32 16
Table 13 Serial dialysis echoes - patient characteristics
median TIME 1 TIME 2
IVSTcm 3 1.6 1.5
PWTcm 3 1.1 1.0
EDDcm 3 5.2 5.1
LVMIg/m2 2 175 162
EDVml 10 125 140
Table 14 Serial dialysis echoes - LV dimensions
Of the two patients beginning haemodialysis for the first time, one 
had a constant LVMI, while the other had an increase from 85 to 
162g/m2.
The LVMI's of 8 patients who had a total of 3 echo examinations 
are illustrated (figure 14) and show no discernible trend.
A moderately strong relationship between change in the mean of 
three systolic blood pressures and change in LVMI between the first two
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Figure 14
Left ventricular mass indices in 8  dialysis patients wtio had 
a series of three echocardiograms
echoes was evident, with a correlation coefficient of 0.585. Mean diastolic 
blood pressure and mean blood pressure on the day of echocardiography 
were less strongly correlated, with rvalues of 0.431 and 0.217 
respectively.
There was also a correlation between change in haemoglobin and 
the change in LVMI between the two echocardiograms (figure 15).
Section 5 ECG and LV hypertrophy
Finally the utility of the electrocardiograph in diagnosing left 
ventricular hypertrophy in a dialysis population was examined.
Using two methods of determining the presence of LVH by voltage 
criteria, the Gubner Ungerleider (337) and the Sokolov Lyon technique 
(338), voltage scores were calculated and compared with the 
echocardiographically determined mass. An LVMI of greater than 109 
g/m^ for women and 134 g/m^ for men was defined as hypertrophy (341).
One hundred and seventy-three satisfactory ECG tracings from the 
time of the echocardiogram were available for the dialysis group. The 
sensitivity and specificity of these two calculations of voltage criteria were 
calculated.
GU LVH+ GU LVH-
ECHO LVH+ 15 110
ECHO LVH- 2 46
Table 15 Gubner Ungerleider (GU) LVH versus echocardiographic LVH
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Figure 15
Correlation between change in haemoglobin and 
change in left ventricular mass index in regular dialysis 
patients
The Gubner-Ungerleider method of determining LVH was unlikely to 
identify the presence of LVH (sensitivity 12%), but was reasonably 
specific for the condition (specificity 95.8%),
SL LVH+ SL LVH-
ECHO LVH+ 61 64
ECHO LVH- 14 34
Table 16 Sokolov Lyon (SL) LVH versus echocardiographic LVH.
The Sokolov-Lyon method was only marginally better with frequent 
false negatives (64/125 - 51.2%) and a low sensitivity of only 48.8%. 
There were also a significant number of false negative results and the 
specificity was only 70.8%.
Section 6  D iscussion
From this cross-sectional survey of a group of typical dialysis 
patients, it can be seen that two electrocardiographic techniques of 
assessing the presence of LVH by voltage criteria have a low sensitivity 
and fail to identify a significant proportion of patients with 
echocardiographic left ventricular hypertrophy. Of the 173 patients who 
had ECG's and satisfactory echoes concurrently, 72.2% had LVH by 
Framingham echo criteria (341). A similar proportion, (73.6%), of the 190 
dialysis patients in whom echo mass could be determined had LVH.
These data indicate that the prevalence of LVH in this population of 
patients appears to be influenced by a number of factors. First, males 
have significantly greater left ventricular mass than females even allowing 
for their increased body surface area. This in part might be explained by a
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higher prevalence of hypertension in men and possibly more severe 
hypertension, as judged by their requirement for a significantly greater 
number of anti-hypertensive drugs.
Whether hypertension, male sex or other factors predispose to the 
greater prevalence of cardiac disease amongst the male dialysis patients 
is not known. It is interesting that patients who had previously suffered a 
myocardial infarction had a significantly higher LV mass index than those 
who had not, the most likely explanantion being that LVH was acting as a 
cardiac risk factor. However the significantly greater end-diastolic 
dimension in the infarct group possibly distorted the determined LV mass 
because of influencing the cube formula.
Use of a "cut-off" LV mass to define the presence or absence of 
hypertrophy is questionable, as this study in common with others shows a 
tendency for LV mass to increase with age. The percentage of patients 
treated for hypertension also rises with age, thereby raising the question - 
is blood pressure alone responsible for the increasing prevalence of 
LVH?
The data on LV dimensions and renal disease would support such 
a role for hypertension as, with the exception of adult polycystic kidney 
disease only, the higher the percentage of patients suffering 
hypertension, the greater the LV mass. Left ventricular mass was highest 
in the small group of 14 patients with renovascular causes of renal failure, 
exactly half of whom had malignant phase hypertension.
Indeed the 12 patients in the total dialysis group who had a history 
of malignant hypertension had marked ventricular hypertrophy, 
particularly of the interventricular septum. This group was too small for 
the median LVMI's to be statistically different from the other hypertensive 
patients' LVMI's, but the median LVMI of hypertensive compared to non- 
hypertensive patients was significantly greater. These observations are in
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accordance with published data on the influence of age. underlying renal 
disease and hypertension on cardiac hypertrophy, but without multiple 
logistic regression analyses it is impossible to attribute independent risk. 
As the patients sampled in this study were recruited for different purposes 
and did not represent the total dialysis population, this statistical method 
was not employed.
Animal experiments suggest arteriovenous shunts equivalent to 
dialysis fistulae can cause myocardial hypertrophy (293) through chronic 
volume overload. In humans, the lack of difference between ventricular 
dimensions of haemodialysis patients with vascular access and CAPD 
patients without, suggests the risk is small. This finding also contradicts 
studies which document a reduction in left ventricular mass with CAPD 
treatment (315,295).
In the cross-sectional survey the median LVMI was greater after 
many years of renal replacement therapy, but this observation was not 
supported by serial echocardiographic measurements in dialysis patients. 
While the LVMI varied considerably with time in individuals no trend was 
evident. This held true, irrespective of the type of dialysis. On the other 
hand, the change in systolic blood pressures, and to a lesser degree, the 
diastolic and mean blood pressures, correlated well with changes in left 
ventricular mass. There was also a relationship between change in 
haemoglobin and change in left ventricular mass index.
In summary, the cross-sectional study highlighted factors which 
might influence ventricular size, most notably blood pressure. The small 
serial study of dialysis patients, also suggested a correlation between 
change in blood pressure and change in LVMI and change in 
haemoglobin and LVMI. It was concluded that dialysis alone, as assessed 
in this project, did not have a predictable effect on left ventricular mass,
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but that other factors, namely blood pressure and possibly haemoglobin 
were likely to be important.
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Chapter 7
RENAL TRANSPLANTATION AND THE LEFT VENTRICLE
Several studies have shown that renal transplantation results in 
regression of left ventricular hypertrophy (295, 321, 322, 323, 324). 
However it is not clear whether this change relates to a reduction in blood 
pressure, amelioration of renal anaemia or resolution of 
hyperparathyroidism. The principle aim of this work was to compare 
changes in LV mass after transplantation with changes following 
erythropoietin therapy or parathyroidectomy, in order to ascertain the 
relative effects of each.
One hundred and fifty-three pre-transplant echoes were recorded, 
but post-transplant repeat echocardiography was only possible in 84 
cases. Early graft failure (18 patients), patient death (11 cases), patient 
transfer (4 cases) and patient refusal to undergo further study accounted 
for the lack of follow-up in a majority of cases.
Echocardiography was repeated within 3 to 5 months in 64 
patients, 6  to 11 months in 10 patients, 12 to 23 months in 8  patients and 
in 2 patients between 24 and 48 months.
One hundred and forty-two (93%) of the patients received 
cadaveric renal grafts and 11 underwent live donor renal transplantation, 
in one case unrelated. Fifteen patients had a series of three echoes.
Following renal transplantation the mean body mass index of the 
entire group of patients rose significantly (table 17). As might be 
expected, there was then a greater need for anti-hypertensive medication, 
but the resultant mean systolic and diastolic blood pressures were lower.
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PRE-TX POST-TX 95%CI p
BMI mean±SD 1.76±0.22 1.81±0.21 (0.03-0.07) p<0.001
SBP median 149 137 (6.0-17.5) p<0.001
DBP meaniSD 90 , 85 (1.00-8.00) p=0.007
 ^BP drugs mean±SD 0.67±0.85 1.2510.92 (-0.87-0.35) p<0.001
Creatinine median 1110 140 (854-989) p<0.001
HB mean±SD 9.110.2 12.311.9 (2.6-3.7) p<0.001
PTHmedian(pmols/l) 18 7 (9.5-26.5) p<0.001
Table 17 Characteristics of patients before and after 
renal transplantation
With successful renal transplantation, serum creatinines fell, the 
mean haemoglobin rose and there was also a significant reduction in 
median parathyroid hormone concentration.
Changes in left ventricular dimensions were also observed with 
considerable variation in the left ventricular masses of the individual 
patients (figure 16), but no overall change in median LVMI (table 18).
This unexpected finding was associated with a tendency for both 
the median interventricular wall thickness and posterior wall thickness to 
increase. The end-diastolic dimension tended to decrease and there was 
a significant reduction in end-systolic dimension. However neither the 
end-diastolic nor end-systolic volume changed.
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Figure 16
Left ventricular mass indices before and after renal 
transplantation (median values shown)
median PRE-TX POST-TX 95%CI p
IVSTcm 9 1.5 1.6 ns
PWTcm 9 1.0 1.0 ns
EDDcm 9 5.2 5.0 ns
ESDcm 9 3.7 3.3 (0.01-0.4) p=0.03
LVlVllg/m2 9 142 137 ns
EDVml 19 138 141 ns
ESVml 19 59 64 ns
Table 18 LV dimension before and after renal 
transplantation
* number of missing values - applies to later 
tables referring to whole group
The group of transplanted patients was divided according to the 
duration of the interval between the first and second echocardiograms, in 
case early changes in ventricular size were being masked (table 19).
INTERVAL
months
PT
NO
PRE-TX
LVMI
POST-TX
LVMI
<3 10 155 163
3-5 54 141 142
6-11 10 135 122
12-23 8 126 118
>23 2 154 98
Table 19 LVMI (g/m^) after varying periods with a renal 
renal transplant
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None of the wall thickness or LV cavity dimensions changed 
significantly for any of the intervals, though changes in the small group re­
assessed for the second time beyond 23 months suggested regression of 
hypertrophy over the longer term. However this trend was not evident in 
the fifteen patients who went on to have a third echocardiogram (table 
20).
median * Pre-tx Post-tx 1 Post-tx 2
IVSTcm 2 1.6 1.7 1.6
PWTcm 2 1.0 1.0 1.1
EDDcm 2 4.8 5.1 5.3
ESDcm 2 3.1 3.2 3.1
LVMIg/m2 2 143 137 137
EDVml 3 123 156 152
ESVml 3 49 68 59
Table 20 LV changes in pateints with 3 echocardiograms
For these patients the mean interval between first and the second 
echo was 5.5 months and the second and the third echo, 8 .6  months.
Section 2
Misoprostol, a prostaglandin analogue and the LV
During the study period, the unit participated in a multicentre 
double-blind placebo controlled trial of the prostaglandin E-j analogue, 
misoprostol (Searie). This was designed to determine whether
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misoprostol prevented cyclosporin nephrotoxicity and acute graft rejection 
in newly transplanted patients. Experimental ischaemic renal injury is 
mitigated by prostaglandin analogues and in rats reversal of cyclosporin 
induced acute renal dysfunction has been described (342). A pilot study 
published in 1990 reported an encouraging and significant reduction in 
the Incidence of acute rejection, but to the authors' surprise, an Increased 
rather than decreased incidence of acute cyclosporin nephrotoxicity 
(343).
As the misoprostol trial had not been planned at the outset of the 
echocardiographic study and the drug was not known to have any cardiac 
effects, the protocol was not interupted. Between June 1989 and January 
1990, 59 adults about to receive a renal transplant were enrolled and 
randomised to receive 1 00  micrograms (meg), 2 0 0 mcg, or placebo four 
times per day. Of these, 54 had pre-transplant echo examinations and 39 
had follow-up scans. Patients continued on their trial drug for twelve 
weeks and their routine treatment was altered in no other way.The drug 
trial codes were not broken until the study was concluded In 1992, by 
which time it was evident that misoprostol had no significant effect on the 
incidence of either acute rejection or cyclosporin nephrotoxicity (344). At 
an investigators meeting a greater than expected incidence of cardiac 
arrhythmias and symptomatic myocardial ischaemia in misoprostol 
treated patients was reported, though not published.
The possibilty that misoprostol might be contributing to the lack of 
expected regression of LV hypertrophy was considered (table 21).
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Misoprostol
Patients *
2 0 0 mcg
n= 1 2
lOOmcg
n= 1 2
placebo
n=13
median pre post pre post pre post
IVSTcm 6 1.6 1.5 1.4 1.6 1.4 1.7
PWTcm 6 0.7 1.0 1.0 1.1 1.0 1.1
EDDcm 6 5.6 5.2 5.2 4.6 5.1 4.8
LVMIg/m2 6 164 165 121 163 135 152
EDVml 8 149 133 140 113 144 148
Table 21 LV dimensions in the misoprostol study showing 
the high dose, low dose and placebo groups
No significant differences were identified between the treatment 
groups, although numbers were small. For these reasons the lOOmcg and 
200 meg groups were combined and the changes which occured in LV 
size during misoprostol administration were compared to the LV changes 
in the placebo treated groups. Only the reduction in end-diastolic volume 
with misoprostol was found to be significant (-5.05 - 7.0) p=0.032. 
Changes in blood pressure, haemoglobin and PTH were comparable in 
the three groups.
As a trend for LVMI to increase was observed in the placebo group 
as well as the active treatment groups, misoprostol was unlikely to 
account for the contradictory findings. Since there were no striking 
changes with misoprostol it was not regarded as a factor which would 
confound other analyses.
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Section 3
Dialysis and subsequent renal transplantation
In the survey of dialysis patients, there were no significant 
differences between the two groups' ventricular dimensions, suggesting 
again that arteriovenous fistulae do not predispose to left ventricular 
hypertrophy. However, could the presence of a fistula in a patient with a 
functioning renal transplant impede regression of ventricular hypertrophy? 
The effects of renal transplantation were therefore compared in those 
patients with functioning vessel access and those patients without.
median
HD
pre
HD
post
HD vs PD
95%CI p
PD
pre
PD
post
IVSTcm 1.5 1.4 ns 1.6 1.8
PWTcm 1 .0 1.0 ns 0.9 1.0
EDDcm 5.2 5.2 (3.67-4.4) p<0.001 5.3 4.8
ESDcm 3.7 3.4 (-0.98-0.20)p=0.004 3.6 3.1
LVMIg/m2 142 129 ns 141 160
EDVml 124 136 ns 141 141
ESVml 56 68 ns 60 62
Table 22 Changes in LV dimensions in haemodialysis patients 
with shunts (n=49) and CAPD patients without (n=35).
Pre and post measurements in each of these groups 
were not statistically different. 95% Cl and p values 
refer to the median changes of the HD group versus 
the PD group.
In haemodialysis patients with fistulae, the end-diastolic diameter 
following renal transplantation remained unchanged, compared to the 
end-diastolic diameter in CAPD patients without vessel access. The
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magnitude of change in the end-systolic diameter was also greater in PD 
patients, implying that AV fistulae or other forms of vascular access are 
associated with ongoing dilatation of the ventricular cavity. End-diastolic 
and end-systolic volumes changed less, but in ways which supported this 
hypothesis.
As well as differing with respect to vascular access, haemodialysis 
patients tend to be more anaemic than CAPD patients because of 
inevitable blood loss and haemolysis associated with haemodialysis.
Section 4
Anaemia LV changes following transplantation
In fact the haemoglobins of the haemodialysis and CAPD patients 
were similar at the time of the first echo (9.2±2.0 and 8.9±1.8 
respectively), perhaps in part reflecting the efficacy of erythropoietin 
therapy which 10% of the haemodialysis patients and 3% of the CAPD 
patients were receiving. The possibility that a higher pre-transplant 
haemoglobin might be reducing the magnitude of subsequent ventricular 
change was examined, by comparing patients with haemoglobins below 
8 g/dl and above 10  g/dl at the time of surgery.
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HB
median *
<8 g/d!
pre
n=26
post 95%CI p
>10g/dl
pre
n=29
post
IVSTcm 4 1.6 1.8 ns 1.6 1.5
PWTcm 4 0.9 1.0 ns 0.9 1.0
EDDcm 4 5.2 4.9 ns 5.3 5.2
ESDcm 4 3.6 3.2 ns 3.8 3.4
LVMIg/m2 4 143 163 ns 123. 129
EDVml 10 143 139 ns 140 149
ESVml 10 72 63 ns 60. 69
Table 23 Comparison of ventricular response to renal 
transplantation in anaemic and less anaemic 
patients
The only significant change to occur in the anaemic patients 
(haemoglobin <8 g/dl), was a decrease in the end-systolic dimension from 
3.6 to 3.2cm (-0.8- -0.125), p=0.009. None of the changes in the less 
anaemic group met with statistical significance.
A comparison of changes in the anaemic and less anaemic groups 
suggested that the end-diastolic diameter was less likely to diminish 
following renal transplanation with a higher haemoglobin. Perhaps as a 
consequence of less ventricular cavity dilatation, the ventricular walls in 
the anaemic patients were thicker post-operatively, but these 
observations did not hold up to statistical testing.
However a weak negative correlation between the change in 
haemoglobin and change in left ventricular mass index after renal 
transplantation was observed (figure 17)
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Figure 17
Correlation between change in haemoglobin and 
change in left ventricular mass index in transplanted 
patients
4.2 Viscosity, transplantation and the left ventricle
Blood viscosity is reported to have an independent effect on 
ventricular hypertrophy (107), and through its relationship with 
haematocrit might be predicted to change after renal transplantation. As 
these laboratory assays could be performed only during working weekday 
hours, not all of the 84 patients had a complete viscosity data-set (table 
24).
median A Pre-tx Post-tx 95% Cl p
SBP 150 135 ns
DBP 90 85 ns
No BP drugs 1 2 ns
HB 8.4 12.8 (2.6-4.65) p=0.000
Whole BV 0 2.24 2.7 (0.195-0.795) p=0.02
Plasma V 0 1.34 1.29 ns
Corrected V 0 3.10 3.09 ns
Relative V 0 2.34 2.38 ns
iVSTcm 1 1.6 1.7 ns
PWTcm 1 1.0 1.0 ns
EDDcm 1 5.0 5.1 ns
LVMIg/m2 1 130 140 ns
Table 24 Blood viscosity (BV) (mPa.s) changes after 
renal transplantation in 26 patients
The whole blood viscosity measured at high shear rates increased 
significantly after renal transplantation, to a median value within the
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normal population range. As plasma viscosity and the corrected viscosity 
remained unchanged, the whole blood viscosity changes were presumed 
to be related to the rise in haematocrit, although increased red cell 
deformability could not be discounted. There was a weak correlation 
between change in whole blood viscosity and change in LV mass 
(r=-0.366).
Section 5
Renal transplant factors and ventricular change
If renal transplantation does genuinely result in a change in 
ventricular morphology, then the degree of change might be related to 
how well the renal allograft is functioning. Chronic rejection is the 
commonest cause of chronic renal dysfunction in transplant recipients, 
which in turn is related to the incidence of acute transplant rejection 
episodes. A patient with an elevated serum creatinine, anaemia, 
hyperparathyroidism and hypertension because of a failing transplant 
shares many of the problems of a dialysis patient, but in addition would 
be receiving immunosuppression.
Ventricular changes after renal transplantation were assessed in 
relation to the serum creatinine at the time of the post-transplant 
echocardiogram (table 25).
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SERUM
GREAT.
< 1 2 0 < 1 2 0 120
-2 0 0
1 20
-2 0 0
2 0 1 -
1000
2 0 1 -
1000
pre post pre post pre post
IVSTcm 1.5 1.3 1.5 1.5 1.7 1.7
PWTcm 0.9 1.0 1.0 1.0 1.0 1.0
EDDcm 4.7 4.8 5.2 5.1 5.9 5.5
ESDcm 3.2 3.2 3.7 3.2 4.1 3.6
LVMIg/m2 116 119 149 138 160 168
EDVml 131 115 136 134 175 173
ESVml 84 63 60 55 100 74
Pt no 26 40 15
Table 25 LV dimensions in relation to final serum 
creatinine (créât).
No significant differences were apparent in the three groups of 
patients who attained different levels of renal function. Similarly there was 
no correlation between the degree of post transplant proteinuria and 
change in left ventricular mass index.
Hypertension is a well recognised side-effect of cyclosporin, now 
the commonest immunosuppressive agent to be used after renal 
transplantation. At the time of the study cyclosporin was being used 
routinely in combination with prednisolone in all patients at least during 
the first year. Four patients with stable transplant function then elected to 
participate in a conversion trial involving changeover to an azathioprine 
and prednisolone regime.
A comparison of the cyclosporin and the four azathioprine treated 
patients (all of whom had initially received cyclosporin), revealed that
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those taking azathioprine had a lower median BP (126/99 vs 137/85) on 
fewer antihypertensives (mean of 0.25 vs 1.3 drugs). The degree of 
change in LVMI in azathioprine and cyclosporin patients was identical, 
although patient number are small.
Section 6 
Males and females
Figure 16 of individual patients' LVMI before and after renal 
transplantation, shows that patients with the highest and lowest LVMI's 
exhibited the greatest degree of change - suggesting regression towards 
the mean. Given that males in the dialysis population had higher LV 
masses than females, there was possibly greater potential for change in 
LVMI in men, but this was not confirmed (table 26).
median
Male
pre
n=50
post 95%CI p
Female
pre
n=34
post
IVSTcm 1.6 1.6 ns 1.4 1.5
PWTcm 1.0 1.0 ns 0.9 0.9
EDDcm 5.3 5.2 ns 4.8 4.8
LVWIIg/m2 159 146 ns 118 126
Table 26 LV dimensions in transplanted men and women
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Section 7
Patient outcome and LV changes after renal transplantation
Mortality from all causes, particularly cardiovascular disease, is 
high in transplanted patients (chapter 1). To determine whether patients 
who died had different cardiac characteristics, the changes after 
transplantation in the surviving transplant patients were compared to 
those in the non-survivors (table 27).
median
Alive
pre
n=73
post 95%CI p
Dead
pre
n=11
post
IVSTcm 1.5 1.5 ns 1.5 1.8
PWTcm 1.0 1.0 ns 0.8 1.0
EDDcm 5.1 5.1 (-1.3-0.04) p=0.037 5.8 4.9
ESDcm 3.5 3.3 (-1.26-0.11) p=0.02 4:3 3.4
LVMIg/m2 131 132 ns 159 169
EDVml 134 139 ns 143 138
ESVml 57 60 ns 63 77
Table 27 LV changes in survivors and non-survivors.
Patients who survived had very little change in either ventricular 
wall or cavity size after renal transplantation. Amongst those who died, 
the initial pre-transplant LV internal dimension was greater, though this 
did decrease subsequently. In the deceased group, both the 
interventricular septum, and posterior wall widths increased, perhaps as a 
consequence of the alleviation of ventricular stretch.
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Section 8 Diastolic function after renal
transplantation.
Diastolic function as assessed indirectly by the left atrial diameter 
and doppler transmitral flow, was markedly impaired as judged by the 
very low E:A ratios, and did not change significantly following renal 
transplantation (table 28).
median * PRE-TX POST-TX 95%CI p
L atrial diam 29 41.3 42.2 ns
E:A ratio 45 0.88 0.96 ns
Table 28 Indices of diastolic function across renal 
transplantation
Nor was there any correlation between changes in E:A ratios and 
changes in LV mass.
Section 9
Patients whose LV mass decreased
The characteristics of 37 patients whose LV mass was lower at the 
time of the follow-up echo were no different from the rest of the transplant 
group. Furthermore the reduction in LV mass could not be attributed to 
change in any one constituent of the heart. In this subset of patients the 
blood pressures, need for antihypertensive medication and the 
haemoglobin and PTFl changes, were indistinguishable from the other 
patients whose LV mass remained stable or increased.
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Section 10
Risk factors for LV hypertrophy and death in transplanted patients
A number of different patient variables were examined by means of 
multiple logistic regression analyses to determine whether they were 
independently related to:-
a) the LVMI at the time of transplantation
b) subsequent patient outcome
The variables (table 29), as recorded on the day of renal 
transplantation were grouped according to whether they were well 
established as cardiovascular risk factors in dialysis populations (group 
1), likely to be associated with LVH or death (group 2), or whether such 
an association was merely speculative (group 3). One-hundred and sixty 
three patients were included in the analysis on an "intention to treat" by 
transplantation basis.
The raw data were log transformed and using multivariate 
regression analysis for each group in turn, the Group 1 covariates SBP 
and EDV were found to be significantly associated with LVMI (p=0.003 for 
each). Applying the same model with group 2 variables, male sex was 
very significantly associated with LVMI and haemoglobin was of 
borderline significance allowing for the relatively small number of 
covariates. When the two groups were combined, the influence of end- 
diastolic volume was countered by haemoglobin. No group 3 variables 
were found to be significant in combination with the important group 1 and 
2 variables. In the final analysis, SBP (p=0.0002) and sex (p=0.002) were 
significantly associated with LVMI, SBP most strongly.
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GROUP 1 GROUP 2 GROUP 3
SBP Sex Aik. phophatase
DBP Body mass index Albumin
MBP Number BP drugs PTH
LVMI Haemoglobin Heart rate
Previous HT Ca X P04 IVST
Diabetes E:A ratio PWT
Smoking habit Age at 1st dialysis EDD
EDV Age at death ESD
Cholesterol Family history L atrial diameter
Triglyceride MWT
Cardiac disease RWT
ESV
Type of dialysis
Table 29 Groups of variables for regression analyses
In the multivariate analysis the true significance of haemoglobin in 
relation to LVMI was difficult to define because of its interaction with end- 
diastolic volume.
The second analysis involved looking at the grouped covariates in 
relation to outcome. Thirty of the original 163 patients died, and a survival 
analysis was performed according to the Cox's proportional hazards 
model. The only variable which was found to be significantly associated 
with outcome was the age at dialysis
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Section 11
Discussion
Renal transplantation in this series resulted in restoration of renal 
function, resolution of anaemia and in most patients hyperparathyroidism, 
but not in the overall reduction in left ventricular mass which has been 
reported in other studies. The data were examined to determine whether 
this difference might be a explained by the length of the follow-up period, 
by the inclusion of 24 patients in a trial of the prostaglandin analogue 
misoprostol, by the continued presence of vascular access, by use of pre­
transplant erythropoietin or by the level of renal transplant function 
attained. None of these factors was found to have a clear or significant 
influence on the lack of change in median left ventricular mass.
Nevertheless, many patients did exhibit a significant individual 
change in LV mass as measured by the validated echocardiographic 
technique, prompting the question - what might be responsible? 
Comparison of patients whose myocardial mass decreased and stayed 
static or increased, provided no clues.
A number of interesting points did emerge; despite no overall 
change In LV mass for the group, there was a tendency for the ventricular 
wall thickness to increase and the cavity size at end- diastole and systole 
to be smaller in the post-transplant period. This did not apply to patients 
with vessel access, in whom there was a suggestion of persisting LV 
cavity dilatation. On the other hand patients with the most severe 
anaemia pre-operatively tended to experience the greatest reduction in 
end-diastolic diameter. There was also a negative correlation between 
change in haemoglobin and change in LV mass.
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Whole blood viscosity increased significantly following renal 
transplantation (in parallel with the rising haematocrit) but there was no 
associated change in ventricular mass.
The patients who died in the early years following renal 
transplanation, had larger ventricular cavities at the time of surgery, 
possibly reflecting previous myocardial damage. However, multivariate 
analysis did not show cavity dilatation to be a significant factor. Only age 
at start of dialysis was associated with subsequent survival.
Male sex and elevated systolic blood pressure at the time of 
transplantation were found to be independent determinants of left 
ventricular mass index. The influence of haemoglobin was less 
conclusive, but of possible importance.
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Chapter 8
ANAEMIA AND THE LEFT VENTRICLE
There is a wealth of experimental evidence to point to the stressful 
effects of anaemia on the myocardium (chapter 3). However, until 
recently, the only successful method of treating the chronic anaemia of 
human renal failure was by blood transfusion which carried risks of 
infection and sensitisation to HLA antigens, caused a degree of volume 
loading and was merely of short term benefit. The advent of recombinant 
human erythropoietin was therefore met with considerable clinical and 
scientific interest. The drug first became available in Glasgow for trial use 
late in 1988, at which time studies of its effects on cardiovascular function 
were awaited. Erythropoietin, or epoietin by its generic name, gained its 
product licence in 1990 and is now in widespread use.
A small early supply of erythropoietin provided an opportunuty to 
study the cardiac effects of correcting anaemia and to compare these 
with the ventricular response to a rise in haemoglobin which occurs 
following successful renal transplantation.
Section 1 Dialysis, anaemia and the left ventricle
To begin with, an exploratory survey of how anemia appears to 
affect the left ventricle in dialysis patients was undertaken (table 30).
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median
Hb<6
n= 1 2
Hb6-7.9
n= 6 8
Mb 8-10
n=74
Hb>10
n=63
SBP 146 146 145 144
DBP 87 88 89 88
BP drugsmean 0.3 0.90 1.15 0.58
PTHpmols/l 30 2 0 27 16
iVSTcm 1.9 1.6 1.5 1.6
PWTcm 1.0 1.0 1 .0 1.0
EDDcm 6 .2 5.3 5.0 5.2
ESDcm 3.5 3.7 3.4 3.5
LVMIg/m2 194 168 146 150
EDVml 160 122 123 142
ESVml 76 61 55 65
E:A ratio 1.03 0.91 0 .8 6 0.84
Table 30 LV dimensions and different degrees of anemia in 
the dialysis population
This suggested that the interventricular septal thickness, the LV 
mass and the end-diastolic volume were all greater in patients with 
severe anaemia (haemoglobin less than 6 g/dl) compared to those with 
haemoglobins of 6 -8 g/dl. These still significantly anaemic patients in turn 
had a higher median LV mass than those with haemoglobins between 8 
and 10g/dl. Above a haemoglobin level of 10 g/dl there was no further 
change. It is also noteworthy that with falling LV mass, the E:A ratio also 
rose progressively and possibly paradoxically, though remained low. 
Severe anaemia associated with LVH might be expected to result in a 
lower E:A ratio signifying impaired ventricular diastolic filling.
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Section 2 The ventricular effects of erythropoietin 
treatment
With the introduction of erythropoietin it was possible to study the 
correction of anaemia and any associated cardiac effects. Twenty 
patients had echocardiograms at the beginning of erythropoietin therapy. 
As treatment had to be dicontinued early in one patient because of 
transient visual loss and another was transplanted, there were follow-up 
echoes in 18 patients after a mean interval of 16.5 weeks. Eleven 
patients were stablished on haemodialysis,6 on CARD and one had a 
failing renal transplant.. There were 11 men and 7 women.
Six of the 18 patients were treated with 50 units/kg of erythropoietin 
(epoietin alfa, Cilag-Biotech ) intravenously three times per week after 
dialysis for the first twelve weeks of treatment, as part of a clinical trial of 
the drug. Thereafter they received a median dose of 2000 units of 
epoietin beta, (Bohringer) subcutaneously three times per week, in 
common with the other non-trial patients. One man experienced transient 
visual loss and discontinued treatment, another required admission with 
uncontrolled hypertension which responded to temporary drug withdrawal 
for 4 days and an increase in antihypertensive medication.
The majority of patients reported benefit within a few weeks of 
starting therapy - improved effort capacity, better appetite, and a 
generally increased sense of well being. In 5 patients, objective exercise 
testing demonstrated prolongation of exercise time and improved oxygen 
uptake at maximal exercise. In one case exercise induced ST segment 
depression on EGG disappeared after erythropoietin treatment.
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PRE-EPO POST-EPO
95% 01 p
BSAmean±SD 1.67±023 1.67±0.24 ns
SBP median 143 143 ns
DBP median 83 87 ns
BPdrugsmeantSD 0.94±1.08 1.47±1.3 (-0.12-0.94) p=0.015
Hb median 6.8 10 .0 (1.65-3.75) p=0.001
PTH pmols/l 11.5 16 ns
CA X P04 5.01 4.7 ns
Table 31 Response to erythropoietin - all patients
A significant rise in haemoglobin was seen with erythropoietin 
therapy (table 31). The median blood pressure did not change, but this 
was only achieved by the prescription of an increased number of anti­
hypertensive drugs.
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median
*
PRE-EPO POST-EPO
95%CI p
IVSTcm 0 1.61 1.6 ns
PWTcm 0 1.0 1.0 ns
EDDcm 0 6.4 5.5 ns
ESDcm 0 3.6 3.6 ns
LVMIg/m^ 0 183 179 ns
EDVml 6 162 176 ns
ESVml 6 75 92 (-93 - -44) p=0.04
E:A 2 1.11 0.98 ns
Table 32 LV dimensions of ail erythropoietin treated 
patients (n=18)
The only significant change to occur in LV dimensions with 
erythropoietin treatment was an increase in end-systolic volume 
(table32). However, lack of change in median LV mass did not signify 
lack of change in individual patients (figure 18). This shows that LVMI fell 
in patients who responded to erythropoietin, but increased markedly in 
the two patients who did not respond to treatment.
The characteristics of the erythropoietin responders (table 33), 
were no different from the group as a whole.
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Figure 18
Change in left ventricular mass indices in patients 
receiving erythropoietin
PRE-EPO POST-EPO
95% 01 p
BSAmeaniSD 1.67±0.25 1 .68 ns
SBP median 143 145 ns
DBP median 83 85 ns
BPdrugsmeantSD 0.87±1.0 1.4±1.2 (0.07-0.995) p=0.027
Hb median 6.8 10.3 (2.1-3.95) p=0.001
PTH pmols/l 11.5 16 ns
CA X  P04 4.9 5.0 ns
Table 33 Erythropoietin responders only (n=16)
Although a tendency for ventricular wall thickness and LV mass to 
fall was evident, the magnitude of change was small, possibly because of 
the small number of patients tested (table 34). The rise in end-systolic 
volume did achieve statistical significance, but the clinical significance of 
this is uncertain.
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median *
PRE-EPO POST-EPO
95%CI p
IVSTcm 0 1.6 1.5 ns
PWTcm 0 1.0 0.9 ns
EDDcm 0 5.4 5.3 ns
ESDcm 0 3.4 3.8 ns
LVMIg/m^ 0 188 152 ns
EDVml 5 169 182 ns
ESVml 5 79 86 (-97- -52)p=0.006
E:A ratio 2 1.1 1.04 ns
Table 34 LV dimensions of patients who responded to 
erythropoietin
Section 3 Blood viscosity and erythropoietin
Blood viscosity measurements were made in 10 of the 
erythropoietin treated patients, all of them responders (table 35). The 
whole blood viscosity increased slightly, but not significantly and the 
plasma viscosity remained unchanged. In all other respects this group of 
10 patients was similar to the complete erythropoietin group. There was 
found to be a negative correlation between change in blood viscosity and 
change in LV mass (r=-0.507).
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median *
PRE-
EPO
POST-
EPO 95% Cl p
SBP - 140 140 ns
DBP - 81 85 ns
BP drugsmean - 1 1.2±1.5 ns
Hb - 6.6±0.6 10.4±1.2 (2.50-4.30) p=0.006
Whole BV ~ 2.02 2.25 ns
Plasma V 1 1.31 1.30 ns
IVSTcm 0 1.5 1.4 ns
PWTcm 0 0.9 0.9 ns
EDDcm 0 5.4 5.4 ns
LVMIg/m2 0 150 141 ns
Table 35 Blood viscosity (BV) (mPA.s) changes with 
erythropoietin
Section 4 Discussion
The patients described in this chapter were amongst the first to 
benefit from treatment with recombinant human erythropoietin. Of the 
eighteen patients who were able to continue therapy, sixteen responded, 
all with an improved sense of well-being and a significant rise in 
haemoglobin. Despite a need for more anti-hypertensive medication, and 
by implication, higher blood pressure, there was a trend for LV mass in 
these patients to fall.
In contrast LV mass increased in the two patients who did not 
respond to erythropoietin with a rise in haemoglobin. Although the
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numbers are small, the observations suggest that successful 
erythropoietin therapy leads to a change in the determined LV mass, 
which could be interpreted as regression of ventricular hypertrophy. 
However, a paradoxical, albeit small increase was seen in wall thickness. 
Despite these changes in LV dimensions which might be expected to 
influence diastolic ventricular function, the E;A ratios did not alter.
Diastolic dimensions (end-diastolic diameter and end-diastolic 
volume) of the ventricle before and after erythropoietin were similar, but a 
significant Increase in end-systolic volume was observed with treatment. 
This too is surprising because if anaemia is genuinely associated with an 
increase in cardiac output, then its correction might be expected to result 
in lower end-diastolic and end-systolic volumes. A possible explanation is 
that the hypoxic vasodilatation of the anaemic state is abolished with 
erythropoietin therapy, increased peripheral vascular resistance results 
and as a consequence of this and the elevated blood pressure, the heart 
dilates. Loss of the heightened contractility associated with anaemia 
might also contribute (253, 254).
The end-diastolic volume and end-systolic volume in the survey of 
anaemic dialysis patients, tended to be lower in patients with higher 
haemoglobins. However few of these patients were receiving 
erythropoietin. Perhaps the combined effects of erythropoietin treatment, 
with its pressor action, and the resolution of anaemia are important in 
explaining these contradictory findings.
Silberberg in his study of anemic dialysis patients, commented only 
upon increased ventricular mass with more severe degrees of anaemia, 
and did not quote measurements of diastolic or systolic cardiac size 
(208).
Since this Glaswegian study was performed, other investigators 
have reported regression of ventricular hypertrophy with erythropoietin
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therapy in small groups of patients (345, 346, 347, 348), using the same 
LV mass formula. While Canella's patients' reduction in LVMI was 
accompanied by variable changes in wall thickness and end-diastolic 
dimension (346, 347), Zehnder's patients showed a significant reduction 
In interventricular septal thickness (348). The changes were confined to 
only the patients whose blood pressure was well controlled. Posterior 
wall thickness did not change and he did not quote figures for end- 
diastolic dimension. It is not clear whether the echo analysis was 
performed blindly.
On the basis of this type of work, it is now widely accepted that 
erythropoietin therapy leads to regression of left ventricular hypertrophy. 
Whether this is a valid conclusion in the presence of changing wall and 
cavity size, remains to be discussed.
The haemoglobin response to recombinant erythropoietin Is less 
than that seen with naturally occuring erythropoietin from a renal 
transplant. This might result from cautious dosing to avoid side-effects 
and costs, but immunosuppression in transplant patients could 
theoretically modify the production or action of erythropoietin though 
cytokine mediated effects in transplanted patients. Such a mechanism 
might explain the polycythaemia which is seen in 10  to 15% of transplant 
recipients. As well as a greater increase in haemoglobin, whole blood 
viscosity also rose further, but no more than would be expected with a 
rising haematocrit.
The ventricular effects of a rising haemoglobin In erythropoietin 
treated patients and transplanted patients are less clearly matched. There 
was a weak relationship between change in haemoglobin and change in 
LV mass in the transplanted patients with a correlation coefficient of 
0.318. Despite the more uniform trends in ventricular change in the 
erythropoietin treated patients, there was no correlation (r=-0.008). A
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negative correlation between change in blood viscosity and change in LV 
mass index was found, which conflicts with Devereux's views on the 
association of blood viscosity and LV mass in hypertensive patients 
without renal failure (107).
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Chapter 9
HYPERPARATHYROIDISM AND THE LEFT VENTRICLE
As hyperparathyroidism may predispose towards left ventricular 
hypertrophy and dilatation (274), and parathroidectomy in primary 
hyperparathyroidism is known to lead to a small reduction in LV mass 
(129), the effect of parathyroidectomy in uncontrolled 
hyperparathyroidism associated with chronic renal failure was 
investigated.
Twelve patients were studied before and after parathyroidectomy. 
Five were on dialysis and six had functioning renal transplants. One 
patient who had parathyroidectomy performed as a dialysis patient 
received a cadaveric renal transplant a month later and was included in 
the transplant group. The main indication for parathyroidectomy was 
refractory hypercalcaemia associated with inapproprately high circulating 
PTH levels. In dialysis patients such hypercalcaemia usually precludes 
use of calcium containing phosphate binders and renders control 
impossible without resorting to aluminium containing potentially toxic 
compounds. Use of vitamin D preparations is also limited by 
hypercalcaemia.
The mean interval between the first and second echo was 21 (±3.8) 
weeks.
The routine surgical procedure at the time of the echo studies was 
subtotal parathyroidectomy with subcutaneous implantation of a fragment 
of parathyroid tissue in the leg. Surgery resulted in a significant fall in 
PTH levels (table 36) without any significant change in blood pressure or 
haemoglobin.
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PRE-PTX POST-PTX
BSAmean±SD 1.76±0.18 1.74±0.19 ns
SBP median 135 137 ns
DBP median 82 77 ns
BP drugs mean±SD 1.0±0.74 0.92±0.1 ns
Hb median 10.3 10.0 ns
PTH pmols/l 96 4 (-134-48) p=0.003
CA X P04 3.7 3.4 ns
Table 36 Patient characteristics before and after 
parathyroidectomy
median PRE-PTX POST-PTX 95%CI p
IVSTcm 1 1.5 1.3 ns
PWTcm 1 1.0 0.9 ns
EDDcm 1 5.1 5.4 ns
ESDcm 1 3.7 3.8 ns
LVIVllg/m2 1 150 141 (-27.9-2.1) p=0.029
EDVml 2 125 121 ns
ESVml 2 49 47 ns
E:A ratio 1 1.1 1.2 ns
Table 37 LV dimension and parathyroidectomy - all 
patients
Both the interventricular septal wall and the posterior ventricular 
wall decreased slightly, though not significantly in size (table 37). The
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derived LVMI however did show a significant reduction (figure 19). No 
volume changes were apparent.
In case ventricular changes after parathyroidectomy are influenced 
by transplant status, the transplant and dialysis groups were examined 
separately.
Section 1 Parathyroidectomy in dialysis 
patients
In the dialysis group, phosphate control in the pre-operative 
situation was difficult, typified by the high median calcium-phosphate 
product. With removal of parathyroid tissue, PTH levels fell and 
phosphate control improved (table 38). Trends for septal thickness and 
LV mass to diminish were still evident (table 39).
PRE-PTX POST-PTX
BSAmeantSD 1.69±0.17 1.74±0.17 ns
SBP median 133 133 ns
DBP median 77 71 ns
BP drugs mean±SD 0.6±0.54 0.2±0.4 ns
Hb median 9.1 9.0 ns
PTH pmols/l 39 7. (-261-110) p=0.059
CA X P04 6.1 3.8 ns
Table 38 Characteristics of 5 dialysis patients undergoing 
parathyroidectomy
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Figure 19
Changes in left ventricular mass indices in patients 
before and after parathyroidectomy
median PRE-PTX POST-PTX 95%CI p
IVSTcm 0 1.5 1.3 ns
PWTcm 0 1.1 1.1 ns
EDDcm 0 5.1 5.6 ns
ESDcm 0 3.3 3.6 ns
LVMIg/m^ 0 185 176 (-45.9-9.4) p=0.059
EDVml 0 132 124 ns
ESVml 0 62 45 ns
E:A ratio 1 1.4 1.1 insufficient data
Table 39 LV dimensions of 5 dialysis patients before and 
after parathyroidectomy
Section 2 Parathyroidectomy in renal transplant 
patients
In the transplanted patients, parathroidectomy did not result in any 
change in LV size or mass (table 41). Unlike the dialysis group there was 
a slight increase in the number of blood pressure lowering drugs required.
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PRE-PTX POST-PTX
BSAmean±SD 1.81±0.19 1.84±0.21 ns
SBP median 135 143 ns
DBP median 83 85 ns
BP drugs meaniSD 1.28±0.76 1.42±0.97 ns
Hb median 10.9 1 1 .6 ns
PTH pmols/l 24 2 (-104-9.0) p=0.022
CA X  P04 2 .8 2.3 ns
Table 40 Characteristics of 7 transplant patients 
undergoing parathyroidectomy
median PRE-PTX POST-PTX 95%CI p
IVSTcm 0 1.5 1.3 ns
PWTcm 0 0.9 0.8 ns
EDDcm 0 5.1 5.3 ns
ESDcm 0 3.8 3.9 ns
LVIVIIg/m^ 0 125 120 ns
EDVml 1 125 120 insufficient data
ESVml 1 48 48 insufficient data
E:A ratio 3 0.97 1.2 insufficient data
Table 41 LV dimensions of transplant patients before and 
after parathyroidectomy
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Section 3 Discussion
Parathyroidectomy in this group of patients was associated with a 
reduction in the derived left ventricular mass. However, this observation 
did not apply in smaller subsets Nevertheless, there was a strong 
correlation between the change in LVMI and the change in parathyroid 
hormone concentration (r=0.843 for whole group, r=0.5 for dialysis 
patients and r=0.97 for transplant patients). Effective removal of 
parathyroid tissue will inevitably result in a fall in PTH, but the strong 
correlation with change in LVMI was surprising because of the variabilty 
of this determinant in the other studies.
Although there was a tendency for the end-diastolic dimension to 
increase after surgery, it is difficult to draw firm conclusions on the basis 
of the small number of patients. There was also a suggestion that the 
dialysis patients whose median LVMI tended to fall needed fewer anti­
hypertensive drugs after parathyroidectomy, while the transplant patients, 
whose LVMI did not change needed more.
In other smaller studies of the left ventricle after parathyroidectomy 
in patients on renal replacement therapy, dialysis patients have been 
studied (277, 278, 276) with conflicting results. Neither G after in a series 
of cardiac assessments over 6 months, nor Zucchelli at 5-8months post- 
parathroidectomy found any significant changes (277, 278). On the other 
hand Druecke reported a significant early improvement in systolic 
function within a fortnight of surgery (276). He performed 
echocardiography but did not describe LV mass. Reduction in LV mass 
following parathyroidectomy in patients on RRT has hitherto not been 
described.
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Chapter 10
DISCUSSION AND FINAL CONCLUSIONS
The first evidence of the importance of left ventricular hypertrophy 
as a risk factor for death from cardiovascular disease and other causes in 
patients with end-stage renal disease was presented when this thesis 
project was just beginning (48). At that time several small uncontrolled 
studies suggested renal transplantation resulted in a significant reduction 
in left ventricular mass (321, 322, 295, 323, 324) but the mechanism was 
not understood. Dialysis patients were known to have multiple problems 
such as hypertension, anaemia and volume overload which might 
predipose to cardiac failure, but the relative importance of these, 
particularly in relation to cardiac hypertrophy in renal disease, was 
unclear.
If left ventricular hypertrophy improved following renal 
transplantation, a study of some of the associated changes in patients not 
undergoing transplantation might provide insight into the mechanisms. 
The introduction of recombinant human erythropoietin provided the 
opportunity to look at correction of anaemia not attributable to 
improvement in renal function. The study of patients undergoing 
parathroidectomy made it possible to compare the cardiac effects of 
correcting hyperparathyroidism with those in transplanted patients. 
Consecutive patients undergoing renal transplantation were studied 
whenever possible and dialysis patients, who were subjected to none of 
these interventions were intended to form another control group.
At the start of the study, Devereux and Reichek’s (51) method of 
determining left ventricular mass was regarded as the best, because it
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had been validated and there was considerable experience of its utility. 
Ventricular diastolic dysfunction was examined in these patients, by 
means of Doppler transmitral flow, because of the lack of evidence of its 
prevalence in renal dialysis patients, the majority of whom have left 
ventricular hypertrophy. End-diastolic and end-systolic volumes were also 
assessed by a simple echocardiographic technique which has not been 
applied in dialysis populations before. The author performed all echo- 
doppler examinations herself and towards the end of the study analysed 
tracings which had been coded anonymously. Echocardiographic and 
analytical techniques were shown to be reproducible.
During the study, a randomised controlled trial of the prostaglandin 
analogue misoprostol was commenced and trial subjects were included in 
the echocardiographic survey.
As most of the patients for whom transplantation, erythropoietin 
therapy or parathyroidectomy was planned, were established on dialysis 
treatment, a cross-sectional analysis of this dialysis population was 
undertaken. Key investigations in the renal field have been performed in 
this manner (208, 349) and the comparative data provided useful 
background information as well as pointing to the types of effects dialysis 
might have on LV morphology, which would merit further study.
Section 1 Dialysis
Men were found to have greater left ventricular masses than 
women, despite adjustment for body surface area. This has been 
suggested in studies of normal subjects (91) but in male dialysis patients 
the differences appear greater, thus highlighting the importance of 
examining male:female ratios in echocardiographic surveys of dialysis 
patients. Echocardiographic examination is recommended, because the
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two electrocardiographic methods of diagnosing left ventricular 
hypertrophy proved in this study to have unacceptably low sensitivities 
and specificities in this dialysis population.
A tendency for LV mass to increase with age was confirmed, and 
the influence of underlying disease on LV mass, particularly with 
reference to the prevalence and severity of hypertension, was illustrated. 
In contrast to other evidence (203), no differences between LV size in 
haemodialysis and CARD patients were identified. A suggestion that LV 
wall thickness might increase with duration of renal replacement therapy 
was not confirmed by serial echocardiography in stable dialysis patients. 
However longer term follow-up might alter this conclusion (295, 202). 
Nevertheless, considerable variablity in LV mass was observed that was 
difficult to explain, but appeared to correlate with changes in systolic 
blood pressure and to a lesser extent haemoglobin. In the dialysis group, 
increasing severity of anaemia, tended to be associated with a thicker 
inter ventricular septum and a greater LV mass. End-diastolic and end- 
systolic volumes were larger in the most anaemic patients with 
haemoglobins of less than 6 g/dl.
Section 2 Renal transplantation
The changes in left ventricular mass which resulted from renal 
transplanation were intended to form the central focus of this thesis. 
However, "blinded" echo analysis did not reveal the expected early 
reduction in LV mass. Instead LV mass changed in a fashion that could 
not be explained by the duration of the follow-up interval or the level of 
renal function achieved by the transplant. The prostaglandin analogue 
misoprostol did not appear to influence the change in LV mass, but may 
have been associated with a greater reduction in end-diastolic volume.
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There was also a suggestion that patients with functioning vascular 
access after renal transplantation, had persisting elevation of both end- 
diastolic and end-systolic dimensions. The degree of change in end- 
diastolic dimension differed between patients who were very anaemic at 
the time of transplant surgery and those who were not. As the end- 
diastolic dimension is a component of the cube formula used to determine 
left ventricular mass, these observations are likely to be relevant.
Diastolic dysfunction was common and did not improve after renal 
transplantation, as judged by E:A ratios. Systolic function was not 
assessed because of the well known difficulties in interpreting the 
influence of preload upon observed changes (300). However, tests of 
diastolic function such as transmitral flow may be equally subject to 
variation in left ventricular end-diastolic pressure and systolic load and 
function (165, 166). The role of this method in the study of dialysis 
patients requires further evaluation before reduced E;A ratios are 
regarded as significant.
In a multiple logistic regression analysis of factors which might be 
associated with left ventricular mass at the time of renal transplantation, 
systolic blood pressure and male sex were found to be significant. 
Haemoglobin was of borderline significance, but a negative correlation 
between change in haemoglobin and change in LV mass after 
transplantation suggested a definite association.
The only variable which was found to be associated with patient 
outcome in this series was age at the start of dialysis treatment. Left 
ventricular mass index per se was not a risk factor, which contradicts 
Silberbergs view (48). Fundamental differences in study design might 
explain these discrepancies - he looked at relative risk based on quintiles 
of left ventricular mass index, rather than at mass as a continuous
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variable, and he assessed a cohort of patients beginning renal 
replacement therapy, rather than a group selected for transplantation.
Section 3 Erythropoietin
In patients who responded to erythropoietin treatment, slight 
reductions in LV wall thickness, end-diastolic dimension and LV mass 
were seen. A contrasting increase in LVMI was evident in the two non­
responders, but despite these changes the correlation between change in 
haemoglobin and change in LV mass index was not strong. This suggests 
other factors had a role. A rise in blood pressure with erythropoietin 
therapy (as judged by a need for more antihypertensive medication) or 
the increase in whole blood viscosity were considered as possible 
opposing forces to ventricular regression. However the change in whole 
blood viscosity exhibited a negative correlation with LV mass and the 
blood pressure measurements were too imprecise to be conclusive. A 
further study including more patients and viscosity measurements with 24 
hour blood pressure recordings would be of interest.
In other reports of regression of LV hypertrophy with erythropoietin 
(345, 350,346, 347, 348) there have been inconsistent changes in wall 
thickness and cavity dimension. The relative contribution of each to the 
overall mass reduction should be further examined before a final 
judgement on erythropoietin's effect on hypertrophy can be given.
Section 4 Parathyroidectomy
Parathyroidectomy resulted in a significant fall in overall left 
ventricular mass, more pronounced in dialysis patients. While some slight 
reduction in LV mass has been demonstrated after surgical
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parathyroidectomy for primary hyperparathyroidism (129), this has not 
been reported in patients on renal repacement therapy. London et a! have 
reported an "inadequate left ventricular hypertrophy" in patients with 
severe secondary hyperparathyroidism (274) who have a degree of left 
ventricular dilatation and hypertrophy, but a reduced mass to volume ratio 
compared to dialysis patients without hyperparathyroidism. The 
interpretation of volume to mass ratios with the current methodology 
requires careful scrutiny.
In order to explain the differences in this series of studies and 
others in the literature, the validity of the Devereux and Reichek's (51) 
formula for determination of LV mass in dialysis patients was questioned. 
Would volume changes alone during a dialysis session influence the 
result?
Section 5 Volume removal and LV measurements
Echocardiographic examination was performed before and after a 
haemodialysis session which involved weight reduction by ultrafiltration in 
twenty patients. The analysis was performed blindly (table 42).
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median PRE-DIAL POST-DIAL 95%CI p
SBP 142 128 (-37--60) p=0.011
DBP 78 68 (-18--40) p= 0.012
WEIGHT 61.9 58.5 (-3.15--2.0) p<0.001
XS w t 2 .2
H Rate 71 85 (3.0-11.5) p=0.015
IVSTcm 1.6 2 .0 (0.13-0.555) p=0.003
PWTcm 1.0 1.1 (0.03-0.235) p=0.04
EDDcm 5.3 4.9 (-0.765- -0.05)p=0.031
ESDcm 4.1 3.5 (-0.665- -0.065) ns
LVMg 276 334 (2.5-78) p=0.042
EDVml 157 155 ns
ESVml 78 58 (-28.0--7.1) p=0.018
E:A 1 .02 1.03 ns
Table 42 Pre- and post- dialysis data in 20 patients
Haemodialysis with weight loss was sufficient to alter the left 
ventricular mass significantly as assessed by Devereux's method. It 
changed by more than 10% in 14 of the 20 patients and was most closely 
associated with a change in the interventricular septal thickness 
(correlation coefficient r=0.742). However, significant changes in 
posterior wall thickness and end-diastolic and end-systolic diameters 
were also seen. Although the median LV mass rose, mass increased in 
twelve patients and decreased in eight. There was also variability in 
interventricular septal wall thickness.
These findings indicate that simple measurements of wall thickness 
and application of a cube formula to determine left ventricular mass in
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dialysis patients are unreliable because volume changes alone will affect 
the results. This was demonstrated in the case of one of the study 
patients who died seventeen days after his dialysis assessment. His 
echocardiographic LVM was 496g before dialysis and 535g afterwards.
At post-mortem the weight of the dissected left ventricle was only 380g 
(figure 2 0 ).
Devereux's method (51) was formulated to take account of the 
Influence of end-diastolic diameter on the cube calculation, but in patients 
who are subject to volume changes, the simple subtraction technique 
appears inaccurate. It Is presumed that a degree of ventricular wall 
stretching around the dilated cavity leads to apparent thinning, and 
removal of excess circulating volume restores ventricular wall thickness. 
However, this might be over simplistic as only weak correlations between 
changes in weight during dialysis and changes in derived left ventricular 
mass (r=-0.344) and interventricular septal thickness (0.021) were 
evident.
None of the left ventricular wall or cavity measurements remained 
constant, suggesting that no single measurement can be used with 
confidence in serial echocardiographic evaluation in dialysis patients. If 
relatively minor weight loss in dialysis patients can cause such profound 
alterations in echocardiographic indices, the effects of diuretic treatment 
in hypertension might also lead to false conclusions about regression of 
hypertrophy with treatment.
Devereux and Reicheck's original formula was and could only be 
validated for single, rather than serial assessments. Serial 
echocardiographic measurement must take into account the possible 
influence of changing intravascular volume.
In dialysis patients, more reliable measurements might be obtained 
if echocardiography were always performed at the patient’s dry weight.
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Figure 20
Sections of the left ventricle of a study patient at 
post-mortem. The dissected left ventricle and 
interventricular septum v\/eighed 380g.
However, accurate definition can be difficult. It has been suggested that 
the diameter of the inferior vena cava at the point where closure is 
evident can be used to define euvolaemia (personal discussion with 
Professor Eberhardt Ritz, Heidelberg, September 1994). There may even 
be scope for defining ideal dry weight in terms of optimum end-diastolic 
diameter or interventricular wall thickness, but further study is required, 
initially with repeated echo measurements of LV dimensions at different 
body weights in the same dialysis patient.
The end-diastolic and end-systolic volumes were also affected by 
fluid removal during dialysis
Section 6 Final conclusions
A variety of observations were made in the course of this project 
which was planned and executed according to the validated and most 
reliable techniques available at the time. The final study of LV mass 
before and after haemodialysis was performed in an attempt to explain 
differences between the findings of this thesis and other published 
reports. It proved to be the most interesting aspect of the overall project, 
as it challenged the established methodology for determining LV mass in 
dialysis patients. All previous descriptions of changes in left ventricular 
mass must now be reviewed in the light of these results. Even the 
definition of cardiac hypertrophy as a risk factor should be questioned as 
the cube formula is now known to be an unreliable tool in patients on RRT 
(48).
However, the risk associated with "left ventricular hypertrophy" - be 
it hypertrophy or ventricular dilatation - still exists. Echocardiographic 
analysis continues to be useful, although its value in serial studies will be 
limited unless care is taken to ensure patients are in a euvolaemic state.
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These conclusions may not be restricted to dialysis patients - short 
term studies of diuretics and vasodilator therapy on LV mass deserve 
further attention. Future research should aim to define individuals "dry" 
body weights before attempting to assess ventricular mass.
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Appendix 1 Normal biochemical and haematological 
ranges
NORMAL RANGE
sodium 135-144 mmols/l
potassium 3.5-5.1 mmols/l
bicarbonate 22-32 mmols/l
creatinine 60-110 umols/l
calcium 2.2-2.65 mmols/l
corrected calcium 2.16-2.53 mmols/l
phosphate 0.8-1.45 mmols/l
calciumxphosphate 1.76 to 3.84
albumin 36-50 g/ialkaline phosphatase 35-130 U/l
PTH <6 pmols/l
haemoglobin 13-18 (male) 12-16 (female) g/di
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Appendix 2 Reference ranges for viscosity
(corrected for body temperature 37°C)
whole blood 
plasma
MALE
mPA.s±2SD
3.52±0.49
1.33±0.10
FEMALE
mPA.s±2SD
3.18±0.48
1.32±0.09
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Appendix 3 Normal cardiac chamber and Doppler 
measurements
Normal cardiac chamber sizes 
(means and ULN = upper limit of normal)
MALE ULN FEMALE ULN Ref
EDDcm 4.9 5.8 4.4 5.3 d l
ESDcm 3.1 4.1 2.7 3.7 d l
iVSTcm 1.0 1.3 0.9 1.2 d2
PWTcm 0.9 1.2 0 .8 1.1 d2
LADcm 3.3 4.2 3.2 3.9 d l
LVMg 176 266 121 201 d2
LVMIg/m2 89 134 69 109 d2
E:A ratios of diastolic LV filling  in healthy adults (165)
AGE years 20-29 30-49 50-74
E:A±SE 2.7±0.4 2.0±0.3 1 .2 ±0 .2
Appendix 4 Patient details
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